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Cardiovascular disease (CVD) imposes a significant burden in terms of morbidity and mortality in 
developed countries.  Asia is likely to see an increase in the burden of these diseases in the next several 
decades.  In developed countries, most CVD relate to atherosclerosis.  Atheroscleorsis is a complex, 
multifactorial disorder.  As such, multiple risk factors contribute to the pathogenesis of CVD.  It has been 
observed that some cardiovascular risk factors, particularly obesity, glucose intolerance, hypertension 
and dyslipidemia, occur in the same individual more often than can be expected by chance.  This cluster 
of abnormalities has become known as the metabolic syndrome.  While the pathogenesis of the metabolic 
syndrome, and its link to obesity, insulin resistance is an important part of it. 
 
Through the studies described in this thesis, we have shown that the metabolic syndrome is common, 
and is associated with a 2-3 fold increase in the risk of CVD in the Singapore population.  Over half of the 
CVD events occurring in our population are attributable to the metabolic syndrome.  We further show that 
the metabolic syndrome is not always associated with the presence of central obesity, even when defined 
using lower cut-points designed for use in Asian populations.  Nevertheless, even in the absence of 
central obesity, individuals with multiple metabolic risk factors are insulin resistant, and experience a 
greater risk of CVD.  To better understand the pathogenesis of the metabolic syndrome, we carried out a 
study to determine whether a biochemical signature of disordered protein metabolism, first identified in 
obese individuals, was independently associated with insulin resistance.  We found that this signature of 
increased branch chain amino acid catabolism was indeed associated with insulin resistance independent 
of obesity.  Through a genetic association study, we also found that polymorphisms at the 
APOA1/C3/A4/A5 locus were important risk factors for dyslipidemia (of the sort associated with the 
metabolic syndrome).  We describe a novel interaction between a polymorphism at the APOA5 locus and 
plasma triglycerides, which may contribute to the development of hypertriglyceridemia at relatively low 




In addition to defining the burden of disease associated with the metabolic syndrome, these studies cast 
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Chapter 1 INTRODUTION & LITERATURE REVIEW  
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1.1   Health burden associated with cardiovascular disease 
Socio economic development, accompanied by rapid urbanization, has resulted in an epidemiologic 
transition in the burden of diseases from those associated with infection and malnutrition, to those 
associated with non-communicable chronic diseases.  Cardiovascular diseases, ischemic heart disease 
in particular, represent some of the major causes of morbidity and mortality in developed countries today.   
These diseases also have a significant economic impact.  Coronary heart disease (CHD) is the leading 
cause of death in most industrialized countries1.  The cost of heart disease and stroke in the United 
States, including health care expenditures and lost productivity from deaths and disability, is projected to 
be more than $475 billion in 2009 (http://www.cdc.gov/NCCDPHP/publications/AAG/dhdsp.htm accessed 
on 7 may 2009). 
 
In developing countries, this transition is still in progress and many populations in Asia can be expected to 
experience in a doubling of the burden of cardiovascular disease (CVD) over the next several decades.   
The increase in CHD mortality and morbidity in Asia has now been documented in Malaysia, Singapore, 
Korea, China, the Philippines, Thailand, and India2. Several reasons have been provided for the increase 
in CHD in Asia3.  Firstly, a decrease in mortality from infection and nutritional deficiencies will result in 
more individuals will reach middle and old age.  It is anticipated that the greatest increases in life 
expectancy will occur in Asia 4.  Secondly, lifestyle and economic changes associated with urbanization 
are likely to increase to higher levels of risk factors for CHD.  In most countries in Asia, serum levels of 
total cholesterol have shown a secular rise that has occurred in parallel with the increase in CHD 
mortality2. Serum total cholesterol tended to be lower in rural compared to urban parts of Asia2. Further 
evidence that urbanization is important comes from the experience of migrant populations.  Japanese 
living in California and Hawaii experience higher rates of CHD than those living in Japan5. CHD mortality 
amongst Chinese living in Singapore is several-fold higher than that seen amongst Chinese living in 
China or Hong Kong6.  Comparison of Chinese living in a rural village in the South of China to Chinese 
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living in an urban environment (Hong Kong or Australia) revealed greater sub-clinical atherosclerosis, as 
measured by carotid intima-media thickness7.   
 
In Singapore, rapid socio-economic development in the past four to five decades has resulted in a 
doubling of the age-standardized mortality from ischemic heart disease between the 1960s and the 1980s  
8.   Today, coronary artery disease/Ischemic heart disease (CAD/IHD) and its antecedent syndromes 
remain the second most common cause of death in Singapore and are increasing with the aging 
population (http://www.moh.gov.sg/mohcorp/statistics.aspx?id=5526). In the Singapore Burden of 
Disease Study  2004 conducted by the Ministry of Health, diabetes mellitus, ischemic heart disease and 
stroke were the top 3 leading cause of premature death and ill-health in Singapore, and together 
accounted for more than one-quarter (28%) of the total disease burden. Ischemic heart disease, stroke 
and lung cancer were also the major contributors to the premature mortality burden (unpublished Data.  
Personal communication, Dr Derrick Heng). 
 
In summary, cardiovascular disease is imposes significant morbidity, mortality and cost upon developed 
countries, including Singapore.  More importantly, cardiovascular disease can be prevented through 
intervention to reduce the levels of risk factors (see next chapter).  For these reasons, the ability to 
identify individuals at increased risk of CVD, understand the pathways involved in its pathogenesis, will 
facilitate these preventive activities.  Rapid socio-economic development, which is occurring in most 
rapidly in many countries in Asia will make the lessons learned in Singapore relevant to the rest of Asia, 
which houses two-thirds of the world’s population. 
 
1.2  The multi-factorial nature of cardiovascular disease 
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Although cardiovascular disease comes in many forms, the epidemiologic transition is producing a 
change in the patterns of cardiovascular disease, in addition to increased rates of cardiovascular 
disease1.  CVD related to atherosclerosis (coronary heart disease and ischemic stroke) are the major 
forms of CVD that affect developed countries. 
 
Atherosclerosis is a disease affecting the intima of large and medium sized  arteries.  It is an inflammatory 
process that appears to begin with the accumulation of lipid in the sub-endothelium of the intima9.  This is 
followed by the influx of inflammatory cells including macro-phages and lymphocytes.  This leads to the 
migration and proliferation of smooth muscle cells and the formation of fibrous tissue, which gradually 
occludes the artery.  In addition to occlusion of the artery, ongoing inflammation can lead to erosion and 
thinning of the fibrous cap of the atheromatous plaque, resulting in rupture and sudden, total occlusion of 
an artery.  When this occurs in a coronary artery, this results in a myocardial infarction.  The processes 
involved in the initiation and promotion of plaque formation as well as their eventual rupture are complex 
and multifactorial.  It should therefore come as no surprise that cardiovascular disease is a complex, 
multifactorial disease and that the identification of individuals at increased risk of CVD requires us to 
consider multiple risk factors. 
 
The Framingham heart Study was initiated in 1948 with the aim of securing epidemiologic data on CVD, 
which encompassed the establishment of the relation of “risk factors”   to CVD10.  Through the 
Framingham heart study, it was found that considering multiple risk factors significantly improved our 
ability to predict CVD 11-13.  Over the years, many different risk factors for CVD have been identified.  
Some of these risk factors are non-modifiable and examples include age, a family history of premature 
CAD or gender, whereas others are potentially modifiable, such as obesity, dyslipidemia, hypertension, 
cigarette smoking and diabetes mellitus.  In a large case-control study for myocardial infarction, it was 
estimated that up to 90% of population attributable risk for myocardial infarction was related to a few, 




1.3  Clustering of obesity, dyslipidemia, hypertension and glucose intolerance-The metabolic 
syndrome 
As early as the 1920’s, investigators observed and reported that several metabolic traits (which are now 
known to be CVD risk factors) tended to cluster, in the sense that that they occurred in the same 
individuals more often than could be expected by chance alone15.  In 1967, Crepaldi described a series of 
6 patients who exhibited diabetes mellitus, dyslipdemia and obesity, in whom a  hypocaloric, low calorie 
diet resulted in improvements in all three of these parameters16.  In 1977, Haller used the term "metabolic 
syndrome" for associations of obesity, diabetes mellitus, hyperlipoproteinemia, hyperuricemia and 
Hepatic steatosis when describing the additive effects of risk factors on atherosclerosis17. In 1977 and 
1978, Gerald B. Phillips developed the concept that risk factors for myocardial infarction concur to form a 
"constellation of abnormalities" (i.e., glucose intolerance, hyperinsulinemia, hyperlipidemia 
[hypercholesterolemia and hypertriglyceridemia] and hypertension) that is associated not only with heart 
disease, but also with aging, obesity and other clinical states. He suggested there must be an underlying 
linking factor, the identification of which could lead to the prevention of cardiovascular disease; he 
hypothesized that this factor was sex hormones18, 19. Since that time, this clustering has been observed in 
multiple populations. In 1988, in his Banting lecture, Gerald M. Reaven proposed insulin resistance as the 
underlying factor and named the constellation of abnormalities Syndrome X. Reaven did not include 
abdominal obesity, which has also been hypothesized as the underlying factor, as part of the condition20. 
 
1.4  Defining the metabolic syndrome in the population 
Since 1999, a number of agencies have proposed definitions of the metabolic syndrome.  These included 
the World Health Organization (WHO), The European Group for the study of Insulin Resistance (EGIR), 
the National Cholesterol Education Program Adult Treatment Panel III (NCEP ATP III) and the 
International Diabetes Federation.  These definitions are summarized in table 1. 
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  WHO EGIR NCEP ATPIII IDF 
Glucose  *FPG >6.0 mmol/l (110 
mg/dl)/IGT/DM 
*FPG >6.0 but not DM FPG >6.0 mmol/l (110 mg/dl) FPG >5.6 mmol/l (100 
mg/dl) 
Insulin  *Highest quartile for population  - 
Blood pressure  160/90 140/90 130/85 130/85 
Triglyceride  >=1.7 mmol/l (150 mg/dl) >2 mmol/l (180 mg/dl) >=1.7 mmol/l (150 mg/dl) >=1.7 mmol/l (150 mg/dl) 
High Density 
lipoprotein Cholesterol 
 Men <0.9 mmol/l (35 mg/dl)  
Women <1.0 mmol/l(40 
mg/dl) 
<1.0 mmol/l (40 mg/dl) Men <1.0 mmol/l (40 mg/dl) 
women <1.3 mmol/l (50 
mg/dl) 
Men<1.0 mmol/l (40 mg/dl)  
Women <1.3 mmol/l(50 
mg/dl) 
obesity  WHR > 0.9 in men or > 0.85 
in women and/or 
BMI > 30 kg/m2  
WC > 94 cm in men 
or > 80 cm in women  
WC > 102 cm in men 
or > 88 cm in women  
*Ethnic specific WC 
Albuminuria  UAE ≥ 20 μg/min or 
albumin:creatinine 
ratio ≥ 20 mg/g.  
   
Table 1.  Definitions of the metabolic syndrome.  WHO=World Health Organizatoinl  EGIR=European Group for the Study of Insulin Resistance; 
NCEP ATPIII=National Cholesterol Education Panel Adult Treatment Panel III; IDF=International Diabetes Federation; WC=waist circumference; 




The two earlier definitions from the WHO and the EGIR included an assessment of insulin 
resistance.  While this recognizes the central role of insulin resistance in the pathogenesis of the 
metabolic syndrome, it posed problems in clinical use because the measurement of plasma 
insulin was not routinely available.  Furthermore, the population distribution of plasma insulin is 
not known for most populations to which the metabolic syndrome is relevant.  Finally, there has 
been little effort to standardize measurement of insulin which means that a definition that includes 
a plasma insulin in the highest quartile for the population is subject to differences related to the 
assay used for the measurement. 
 
In 2001, the National Cholesterol Education Program, in formulating the recommendations of 
Adult Treatment Panel III, elected to include a definition of the metabolic syndrome that included 
only commonly measured risk factors for CVD, and identified individuals with the metabolic 
syndrome as candidates for therapeutic lifestyle modification in order to reduce the risk of CVD21.  
The diagnostic criteria included an assessment of each of the 4 traits most commonly associated 
with insulin resistance, namely central obesity, dyslipidemia, hypertension and glucose 
intolerance.   This was not meant to be a comprehensive list of all traits that cluster together, but 
rather a set of commonly available measurements that could be used clinically (personal 
communication, Prof Scott Grundy).  This simple, readily applied, recommendation has led to a 
large increase in the number of publications related to the metabolic syndrome.  In 2006, the 
international diabetes federation adopted the same criteria (with some minor variations (some of 
which are relevant to the projects in this thesis)22. 
 
1.5 The assessment of obesity in Asian populations. 
The assessment of obesity in humans (particularly in clinical practice) is largely dependent on the 
use of simple anthropometric measurements.  The most commonly used is the body mass index, 
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which is the weight in kg of an individual divided by the square of the height. This was developed 
in caucasians as an estimate of fat mass.  The World Health Organization categorizes individuals 
based on the BMI into those who are overweight (BMI>=25 kg/m2), and obese BMI>=30 kg/m2.   
While the BMI is highly correlated with the degree of adiposity, it is not a precise measure of 
adiposity, which requires more detailed, intensive methods such as underwater weighing or 
isotope dilution.   
 
 
As mentioned in a previous section, the rates of CVD is increasing rapidly in Asia, and in more 
developed countries like Singapore, rates are as high, if not higher than in Western countries.  
The same is true of type 2 diabetes mellitus.  Singapore has a high prevalence of T2DM.  All of 
this is occurring despite an average BMI in these countries that is well below the cut-off point of 
25 kg/m2 that defines overweight in the current WHO classification. There is increasing evidence 
that the associations between BMI and  percentage of body fat, and body fat distribution differ 
across populations.  Specifically, BMI may underestimate the degree of adiposity in Asian 
populations.  For example, persons in Singapore have a greater degree of adiposity than 
Caucasians, for the same body mass index23.  This means that, if we want to identify overweight 
or obese individuals with the same degree of adiposity in Singapore, as, for example,  in the 
United States, we would have to define overweight or obesity using lower cut-points for the BMI.   
 
The Marseilles physician Dr. Jean Vague, in 1947, observed that upper body obesity appeared to 
predispose to diabetes, atherosclerosis, gout, and calculi24.  Over time, this has evolved into the 
belief that intra-abdominal fat, contributes more to insulin resistance than subcutaneous fat.  A 
number of hypotheses have been advance to explain this observation.  It has been suggested 
that visceral fat is metabolically distinct from subcutaneous fat25.  In addition, the anatomical 
position of the intra-abdominal fat depot is such that visceral fat drains via the portal system to the 
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liver, which is an important organ involved in glucose homeostasis, and that this results in a 
greater impact on hepatic glucose metabolism.   Obviously,intra-abdominal fat mass cannot be 
readily measured in humans.  However, it has been shown that anthropometric measures of 
central obesity, offer an estimate of intra-abdominal fat mass26.  Several anthropometric 
measures have been utilized for this purpose but the one most common used in recent years is 
the waist circumference, which has been shown to correlate with intra-abdominal fat mass using 
imaging techniques27.  Recently, it has been shown that the  ethnic difference in the relationship 
between BMI and adiposity also applies to relationship between waist circumference and  intra-
abdominal fat mass28-30.  It has been shown that for the same waist circumference, individuals of 
different ethnic background carry different amounts of intra-abdominal fat.  As such, the use of 
the waist circumference in different ethnic groups may result in a systematic over -or under-
estimation of intra-abdominal fat mass.  In the Asian context, the intra-abdominal fat mass is 
under-estimated by the waist circumference29, 30.   
 
In this regard, we have previously shown that the presence of multiple metabolic risk factors 
(particularly diabetes mellitus and dyslipidemia) occurs at lower levels of waist circumference 
than the 102cm in men, and 88 cm in women proposed in the NCEP ATPIII recommendations31.  
On this basis , we have suggested that a definition of central obesity in Asians use a cut-off of 
90cm in men and 80 cm in women, a recommendation that has been adopted by both the 
American Heart Association/National Heart Lung and Blood Institute (AHA/NHLBI)21, as well as 
the International Diabetes Federation (IDF)22. 
 
The use of these modified criteria for the assessment of central obesity led to a large increase in 




Table 2.  Impact of changing the criteria for defining central obesity on its prevalence by gender 
and ethnic group in Singapore (from Tan CE et al31). 
 NCEP ATPIII criteria Asian criteria 












Chinese 3.7(3.0–4.7) 6.9(5.9–8.2) 26.2(24.2–18.2) 21.0(19.3–23.0) 
Malay 4.8(2.9–7.8) 22.0(17.6–27.0) 29.8(24.9–35.2) 43.2(37.7–48.9) 
Indian 8.6(5.3–13.6) 25.5(19.5–32.6) 41.4(34.5–48.7) 53.8(46.2–61.2) 




The inclusion of the Asian criteria for central obesity in the definition of the metabolic syndrome 
increased the prevalence of the metabolic syndrome from 12.2% (95% CI 11.3–13.2) to 17.9% 
(16.8–19.0)31, which is similar to that observed in the United States and other developed 
countries.  However, equating the prevalence to that in other countries is a poor reason to modify 
the diagnostic criteria.  The definition of the metabolic syndrome by the NCEP ATP III was for the 
purpose of identifying individuals at increase risk of cardiovascular disease.  As such, it is 
important to ascertain the impact of these new criteria on the risk of cardiovascular disease in our 
population.  This constitutes the aim of the first study in this thesis. 
 




Obesity is a key feature of the metabolic syndrome, and an important determinant of insulin 
resistance.  Many studies, including our own, have shown that higher levels of obesity are 
associated with greater levels of insulin resistance 32. The pathways linking obesity and insulin 
resistance are complex and heterogeneous.  Two important pathways involve a)  fatty acids and 
b)  inflammation. 
 
1.6.1  Fatty acids as the link between obesity and insulin resistance. 
Adipose tissue was the site where excess energy was stored, in the form of triglycerides (TGs), 
and where that energy, when needed elsewhere in the body, was released in the form of  fatty 
acid (FA).   During hyperinsulinemia, as occurs in the post-prandial state, triacylglycerol clearance 
from lipoproteins and fatty acid trapping are specifically up-regulated  in adipose tissue33, 34.  
Furthermore, adipose tissue is the only site of release of fatty acids when energy is needed (as 
occurs in the fasting state).   Obesity is associated with increased levels of free fatty acids, which 
may have an important role in the pathogenesis of insulin resistance associated with obesity.  
Over 40 years ago, Randle et al35 proposed a mechanism for fat-induced insulin resistance that 
implicated fatty acid oxidation as causing the inactivation of mitochondrial pyruvate 
dehydrogenase and ultimately leading to decreased glucose uptake. They speculated that 
increased fat oxidation was responsible for the insulin resistance associated with obesity and 
hypothesized that intracellular fatty acid accumulation would lead to an increase in the 
intramitochondrial acetyl coenzyme A (CoA)/CoA and NADH/NAD+ ratios, leading to inhibition of 
pyruvate dehydrogenase and increasing concentrations of intracellular citrate. The citrate 
accumulation would inhibit phosphofructokinase, a key rate-controlling enzyme in glycolysis, 
increasing intracellular glucose-6-phosphate concentrations and inhibiting hexokinase II activity. 
The inhibition of hexokinase II activity would result in an increase in intracellular glucose 
concentrations and decreased muscle glucose uptake. However, their work was done in isolated 
rat heart muscle, which may be metabolically very different from resting human skeletal muscle.  
Recent work using NMR spectroscopy to measure intracellular levels of metabolites under 
hyperinsulinemia clamp conditions have suggested that the insulin resistance resulting from 
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excess free fatty acids results from reduced glucose transport and it’s subsequent 
phosphorylation 36, which is much earlier in the glycolytic process than proposed by Randle.  
These defects in glucose transport and hexokinase were similar to previous findings in patients 
with type 2 diabetes 37. and in the lean, normoglycemic offspring of diabetic patients38.  
Subsequent studies have suggested that  exposure to fatty acids could lead  to a serine/threonine 
phosphorylation cascade and increased serine phosphorylation of IRS-1 (and possibly IRS-2) at 
critical sites which block  tyrosine phosphorylation of IRS-139.  The latter is  an important event in 
the insulin signaling cascade. 
 
 
1.6.2  Inflammation as the link between obesity and insulin resistance 
 Obesity is a pro-inflammatory state.  Multiple studies have shown an association between 
obesity and the levels of inflammatory markers including fibrinogen, TNF-alpha, IL-6, and C-
reactive protein (CRP)40-44. Adipose tissue from obese mice  and humans is infiltrated with 
macrophages45, 46   In these studies, adipose tissue was  shown to contain bone marrow–derived 
macrophages, and the  content of these macrophages tracked with the degree of obesity  45, 46. In 
fact, more than 40% of the total adipose tissue cell  content from obese rodents and humans was 
comprised of macrophages  compared with approximately 10% in lean counterparts  45.  These 
macrophages produce inflammatory cytokines, which play an important role in the pathogenesis 
of insulin resistance.  In fact, the pathway involving serine/threonine phosphorulation of IRS-1 
leading to attenuated insulin signaling was first described in relation to the ability of the 
proinflammatory cytokine TNF-impairs insulin action47-49. Specifically, phosphorylation of these 
serine residues  impedes the normal association of IRS-1 with the insulin receptor,  thereby 
impairing downstream propagation of insulin signaling 39, 50. 
 
 
In summary, a number of metabolic pathways have been implicated that may link obesity and 
insulin resistance.  Several, including those involving fatty acids and inflammation, converge on 
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the insulin signaling cascadee.  Specifically, elevated levels of free fatty acids, amino acids and 
TNF-alpha, are associated with obesity and through a variety of mechanisms, result in the 
phosphorylation of serine and threonine residues on IRS-1.  In turn, this results in reduced 
phosphorulation of IRS-1 at tyrosine residues, a key step in the insulin signaling cascade. 
 
1.7 Obesity as a pre-requisite risk factor for defining the metabolic syndrome 
The literature linking obesity (particularly central obesity) and insulin resistance are so compelling 
that, in making their recommendations for the diagnosis of the metabolic syndrome, the 
international diabetes federation lists central obesity as a prerequisite risk factor for the diagnosis 
of the syndrome.  In this regard, the IDF definition differs from that of the AHA/NHLBI, where the 
presence of  central obesity is “optional”.  It has been suggested that the proportion  of individuals 
without central obesity  who have three or more components of  the metabolic syndrome is small 
51, 52. It  is also felt that in the U.S., for the most  part, the same individuals will be identified  by 
either definition so that differences  in the definitions are probably insignificant21  . However, this 
has not been  assessed in various populations, particularly  in populations comprising ethnic  
groups from Asia. Furthermore, the impact of central obesity as an pre-requisite risk factor as 
opposed to an optional  component  of the metabolic syndrome has not  been extensively 
assessed in relation to either insulin resistance or  the risk of ischemic heart disease (IHD).  This 
is particularly pertinent given the finding that, obesity (as assessed by BMI) only explains 22% of 
the variance in insulin resistance in humans (Abassi ), raising the possibility that insulin 
resistance may occur in the absence of significant obesity, or that some individuals may be prone 
to develop the features of insulin resistance a relatively low levels of obesity.  The second and 




1.8 Disordered protein metabolism in the pathogenesis of insulin resistance. 
While insulin resistance is often thought of as a disorder of carbohydrate metabolism, it is 
increasingly obvious that the metabolism of other nutrients is also disordered in the insulin 
resistant state. While an extensive body of literature exists in relation to fatty acids and their role 
in the pathogenesis of insulin resistance, disordered protein metabolism has also been implicated 
in the pathogenesis of insulin resistance and has been much less extensively studied.  Felig et al 
reported high amino acid levels were observed in obese individuals which declined after weight 
loss as early as 1969 53.  Linn et al found that 6 months of high protein intake  induced several 
features of insulin resistance including increased fasting glucose level, impaired suppression  of 
hepatic glucose output by insulin,  and enhanced gluconeogenesis54.  Using NMR techniques 
(similar to those described in relation to the study of free fatty acids and insulin resistance), 
investigators have reported that amino acids – like free fatty acids – directly inhibit skeletal 
muscle glucose transport/phosphorylation 55.  Furthermore, activation of mTOR/S6K by AAs leads 
to serine phosphorylation of insulin receptor substrate-1, and thereby interferes with early steps of 
insulin signaling   56, 57.    It was recently demonstrated that obese humans exhibit a signature of 
elevated branch chain amino acids (BCAAs) suggesting enhanced branch chain amino acid 
catabolism 58.  It was further shown that a diet supplemented with branch chain amino acids 
synergistically increased the effect of a high fat diet on insulin resistance in rats, and result in 
phosphoryation of serine/threonine residues on IRS-1.  While the link between obesity and fatty 
acids and inflammation seem obvious, the link between obesity and elevated amino acid levels 
are less obvious.  In their paper, Newgard et al suggested that the rise in BCAA in blood of insulin 
resistant subjects may be due in part to increased protein intake in obese individuals, an idea 
supported by rat feeding studies in which supplementation of a high fat diet with BCAA caused a 
rise in circulating BCAA and their metabolites, and contributed to development of insulin 
resistance.  However, in their experiments, the animals which consumed a high fat diet 
supplemented with branch chain amino acids gained less weight, and yet were more insulin 
resistant, than those that just consumed a high fat diet.  This suggested that the elevations in 
amino acids may have an impact on insulin resistance that is independent of obesity.  The extent 
28 
 
to which abnormal protein metabolism this contributes to insulin resistance independent of 
obesity is incompletely understood.  The fourth study in this thesis explores this by examining the 
relationship between free fatty acids, inflammatory markers and plasma amino acids and insulin 
resistance, after controlling for obesity. 
 
 
1.9  Dyslipidemia in the metabolic syndrome-The atherogenic lipoprotein phenotype 
1.9.1  Lipid metabolism in health individuals 
Lipids are carried in the plasma as part of lipoproteins.  There are particles that contain a lipid 
core, and are surrounded by a layer of phospholipids.  Embedded in the phospholipid layer are 
apolipoproteins, which are proteins that facilitate the interaction between lipoproteins and other 
proteins (eg enzymes) or receptors.  In this fashion, these apoliproteins regulate the metabolism 
of the lipids in the lipoproteins and also the transfer of lipid to and from lipoproteins. 
 
Lipoproteins can be divided into several major classes based on their size or density.  They also 
contain different apolipoproteins on their surface.  The largest of the lipoproteins are 
chylomicrons, which are produced in the intestine following the ingestion of a meal.  They contain 
large amounts of triglycerides (TG).  In the circulation, chylomicrons are acted upon by lipoprotein 
lipase (an enzyme that is bound to the inner surface of the capillaries), and hydrolyse lipids.  The 
free fatty acids and glycerol released from the chylomicrons can then be stored or used for 
energy production.  This portion of the pathway, involving the transfer of lipids from the diet into 
tissues where they can be stored or used, is called the exogenous pathway of lipoprotein 




There is also an endogenous pathway through which lipids synthesized in the liver are transferred 
to other tissues.  The lipid packages lipids into very low density lipoproteins (VLDL).  These are 
the predominant triglyceride containing lipoproteins present in the plasma in the fasting state and 
elevated levels give rise to elevated fasting plasma triglycerides.  VLDL particles are secreted into 
the circulation where they are acted upon by lipoprotein lipase and are remodeled to smaller, 
denser particles called low density lipoproteins.  Low density lipoproteins (LDL) interact with a 
number of receptors, most importantly the LDL-receptor, and cholesterol is taken up into tissues 
for utilization or back to the liver for excretion as bile acids.  Excess levels of LDL lead to 
deposition of LDL in the sub-endothelium of the arteries, where they initiate the process that is 
atherosclerosis.  For many years, it was thought that LDL was the predominant lipoprotein 
involved in the pathogenesis of atherosclerosis.  More recently, it has been appreciated that 
some of the TG rich lipoproteins can also cross the endothelium and may participate in the 
atherosclerotic process59.  In a similar manner, while plasma cholesterol (particularly LDL-
cholesterol) is a well established risk factor for CVD, the independent contribution of TG has been 













Figure 1. Exogenous and Endogenous pathways for lipoprotein metabolism 
 
There exists a third pathway for lipid transport, which is reverse cholesterol transport.  This is the 
pathway through which excess cholesterol in the tissues are returned to the liver for excretion in 
the bile and involves high density lipoproteins (HDL).  Small lipid poor particles containing mostly 
apolipoprotein A-I (APOA-I) are secreted by the intestine.  They interact with transport proteins in 
the peripheral tissues and acquire cholesterol and phospholipid, increasing in size (figure 2).  The 
cholesterol in HDL then has one of several fates.  It can be taken up by the liver through a 
process of selective cholesterol uptake.  The HDL particle docks with a receptor call scavenger 
receptor class B type I.  Cholesterol is taken up into the liver and the apolipoproteins and 
phospholipids are re-cycled to take up more cholesterol.  Another important pathway for reverse 
cholesterol involves the transfer of cholesterol from HDL to VLDL and LDL, in exchange for 
triglyceride.  This occurs via a protein called cholesterol ester transfer protein (CETP).  This 
reverse cholesterol transport is thought to be responsible for a large part of the observation that 




Figure 2.  Pathway for reverse cholesterol transport.  CETP=cholesterol ester transfer protein;  
LCAT=lecithin cholesterol acyl transferase;  Ch:  cholesterol;  PL =phospholipids;  
CE=Cholesterol ester;  TG:  triglyceride;  HL:  Hepatic Lipse;  SR-BI:  Scavenger Receptor Class 
B Type I; FA=fatty acids. 
 
The rate of this CETP mediated lipid transfer is determined by 3 factors, the importance of which, 
in relation to the dyslipidemia associated with insulin resistance, will become obvious in the next 
section.  The 3 factors are: 
 
1)  The availability of donor particles (VLDL or LDL) 
2) The availability of acceptor particles (HDL) 
3) The concentration and activity of CETP. 
 
1.9.2  Lipoprotein metabolism in the insulin resistant state 
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Dyslipidemia is a key feature of the metabolic syndrome.  Specifically, insulin resistance is 
associated with a particular pattern of dyslidemia, which includes elevated levels of plasma 
triglycerides and low HDL-C.  Normally, insulin inhibits hepatic VLDL secretion, so that in the fed 
state, VLDL secretion is low. Insulin resistance causes loss of this inhibition, leading to increased 
VLDL secretion. As such, in insulin resistant individuals, there is increased VLDL production 
leading to a moderate degree of  hypertriglyceridemia62.  While the precise molecular 
mechanisms of insulin resistance– driven hepatic VLDL overproduction remain undefined, a 
major factor is believed to be the increased flux of fatty acids from adipose tissue to the liver in 
this state. The liver is quite efficient in taking up fatty acids from the circulation. Although β-
oxidation of fatty acids is one important metabolic fate in the liver, many fatty acids delivered to 
the liver by the circulation are re-esterified into TG63. Newly synthesized hepatic TG can be 
loaded onto apoB-100 and incorporated into VLDL for secretion resulting in elevated plasma 
triglycerides.  In addition, LPL activity is reduced in obese  or insulin resistant subjects.  As 
described, LPL is important for the hydrolysis of TG in VLDL, and this also contributes to the 
elevated TG levels observed in the insulin resistant state. 
 
In addition to causing elevated plasma triglyceride levels, the greater availability VLDL particles 
(as donors for CETP mediated  lipid transfer) drives an increased rate of CETP-mediated 
exchange, thus resulting in a greater siphoning of cholesterol out of HDL and reduction in HDL-C 
levels64. Furthermore, the CETP-mediated transfer process enriches HDL with triglycerides, 
resulting in a TG-rich HDL that is a better substrate for hepatic lipase65 Obese insulin-resistant 
patients have TG-enriched HDL and also have higher levels of hepatic lipase activity66.  
Hydrolysis of HDL TG by hepatic lipase leads to the formation of smaller HDL particles that are 
more rapidly catabolized67 (Figure 4). results in greater exchange of triglycerides on VLDL for 
cholesterol on HDL.   For these reasons, there is often an inverse relationship between TG and 
HDL-C in the plasma, and both eleveated TG and low HDL-C are features of the metabolic 
syndrome.   
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It is also important to note that HDL-C can also be low for reasons that are unrelated to elevated 
VLDL.  For example, reduce APOA-I production, the major structural apolipoprotein on HDL, can 
also impact on HDL-cholesterol levels.   
I have only described those aspects of lipoprotein metabolism that are pertinent to the next 
portion of this thesis.  There are many other mechanisms (reviewed in 62) that may contribute to 
the dyslipidemia associated with obesity and insulin resistance which are beyond the scope of 
this thesis.    
 
1.10  The APOA1/C3/A4/A5 locus and dyslipidemia 
There exists, on chromosome 11 in humans, a cluster of genes encoding several apoliproteins 
that play a key role in the metabolism of triglyceride rich lipoproteins and HDL (the lipoproteins 
that are most disordered in the metabolic syndrome68.  This is the APOA1/C3/A4/A5 locus. 
 
As already described, APOA-I is the major structural apolipoprotein in HDL and reduced 
expression of this protein can result in reduced HDL-C.  Overexpression of the human APOA1 
gene (hAPOA1) in mice increased plasma HDL concentrations and protected the animals from 
the development of diet-induced atherosclerosis 69. Conversely, APOA1 knockout mice exhibited 
decreased HDL levels and developed atherosclerotic lesions 70.  
 
Apolipoprotein C-III (APOC-III) is a component of triglyceride-rich lipoproteins and HDL. It is 
synthesized mainly in the liver and to some extent in the intestine68. The major physiological role 
of APOC-III appears to be as an inhibitor of lipoprotein lipase71. Therefore, plasma APOC-III 
concentrations are positively associated with triglyceride concentrations. Consistent with this role, 
overexpression of the human APOC3 gene in mice resulted in dramatically increased plasma 
triglyceride concentrations, and increased atherosclerosis72. Conversely, mice lacking the APOC3 
34 
 
gene had lower plasma triglyceride levels resulting from the faster clearance of postprandial 
triglycerides 73.  
 
Apolipoprotein A-IV (APOA-IV) was first identified as a component of chylomicrons and HDL 74, 
75[15,16]. Although the role of APOA-IV remains unclear, it has been shown that the 
overexpression of APOA-IV at supraphysiological levels in mice had a protective effect against 
the formation of diet-induced aortic lesions. However, these mice also showed elevated 
triglyceride, HDL-cholesterol, and total cholesterol levels. An apolipoprotein homolog of rat 
APOA-IV in human plasma. 
 
 
Apolipoprotein A-V (APOA-V) on TG rich lipoproteins may enhance LPL activity, either directly or 
by facilitating the binding of VLDL to LPL attached to heperan sulphate proteoglycans.   
 
Multiple polymorphisms at the APOA1/C3/AIV/AV locus are associated with altered levels of 
plasma lipids76.  The most consistent associations have been demonstrated for variants at the 
APOC3 and APOA5 loci.   
 
The SstI polymorphism at the APOC3 locus has been most extensively studied and in most, 
though not all 77, populations studied, the presence of the minor allele is associated with elevated 
TG.  In 1995, Li et al found a number of polymorphisms in the APOC3 promoter, which were in 
strong linkage disequilibrium with the SstI polymorphism (which is in an intergenic region) 78.  It 
was shown that the minor alleles at these promoter polymorphisms (particularly those at positions 
-482 and -455 were associated with impaired suppression of APOC3 promoter activity by insulin.  
Li hypothesized that these “functional” polymorphisms in the APOC3 promoter were responsible 




Strong associations have also been observed in relation to polymorphisms at the APOA5 locus 
and TG.  In a German population, 2 haplotypes at the APOA5 locus were associated with 
hypertriglyceridemia.  One contains 4 SNPs in Strong LD and another containing a coding SNP 
S19W.  It was found that the haplotype containing the 4 SNPs was strongly associated with all 
the minor alleles for all 3 APOC3 SNPs (SStI, -482 and -455) whereas the other haplotype was 
not.  Interestingly, in this population, no association was observed between any of the APOC3 
SNPs and plasma TG 79.  In a similar study carried out in the United Kingdom, a similar pattern of 
associations were observed.  The S19W polymorphism was independently associated with 
plasma triglyceride.  However, in this study, polymorphisms at the APOC3 locus were associated 
with elevated TG, but it was suggested that the TG raising effect of the APOC3 SNPs may reflect 
LD between the -1131T>C polymorphism and the APOC3 polymorphisms.  Two small studies in 
Taiwan80  and one in India81 also identified polymorphisms at this locus as being important 
determinants of plasma TG.  However, only a limited number of SNPs were studied and the 
independent role of APOC3 SNPs was not clearly delineated.  Nor did these studies examine 
SNPs in the APOA4 locus.  In a previous study, we studied polymorphisms at the APOA5 locus.  
The S19W was rare in our population as it was in other populations of Chinese ethnicity.  
However, no data is available in relation to other SNPs at this locus and how they may contribute 
to TG in our population.  Furthermore, another coding SNP has been identified in Chinese in 
Taiwan and in the United States82.  This SNP has not been examined in our population.  It 
remains unclear whether the associations between polymorphisms at the different loci in this 
cluster represent independent associations.  Thus, to fully understand the contribution of the 
APOA1/C3/A4/A5 locus to dyslipidemia (particularly in relation to elevated TG and low HDL, the 
typical dyslipidemia associated with the metabolic syndrome) in study 5, we genotyped 62 SNPs 




Subsequently, another study reported that the polymorphism at position -455 modified the 
association between plasma insulin and TG rich lipoproteins in humans83.  This raised the 
possibility that polymorphisms at this locus may modulate the association between obesity (which 
is associated with elevated plasma insulin) and blood lipids.  This finding has not been replicated 
and in this study, we will also explore any interactions between obesity and genetic variants 





Chapter 2 AIMS 
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The following are the aims of the 5 studies that comprise this thesis 
Study 1  Modification of the NCEP ATP III definitions of the metabolic syndrome 
for use in Asians identifies individuals at risk of ischemic heart disease 
1) To examine the risk of ischemic heart disease (IHD) associated with the MS in an Asian 
population 
2)  to examine the effect of modifying the NCEP ATP III criteria for the MS (lowering of the 
WC to 80 cm in women and 90 cm in men) on the risk of IHD associated with the MS.  
 
Study 2  The Impact of Central Obesity as a Prerequisite for the Diagnosis of Metabolic 
Syndrome 
Following the publication of data from study 1, the International Diabetes Federation 
recommended criteria for the diagnosis of the metabolic syndrome, in which the presence of 
central obesity was required to be present as one of the criteria for the metabolic syndrome.  This 
was in distinct contrast to the NCEP ATP III and subsequently, the American Heart Association 
(AHA)/National Heart Lung and Blood Institute, which required the presence of multiple risk 
factors for the diagnosis of the metabolic syndrome, but did not specify a requirement for the 
presence of central obesity.  Thus study 2 was carried out: 
1)  To compare the prevalence of metabolic syndrome (MS) defined according to the 
American Heart Association (AHA)/National Heart Lung and Blood Institute (NHLBI) and 
the International Diabetes Federation (IDF)  
2) to compare the phenotype (insulin resistance and other cardiovascular risk factors) 




Study 3  Should Central Obesity Be an Optional or Essential Component of the Metabolic 
Syndrome?  Ischemic heart disease risk in the Singapore Cardiovascular Cohort Study 
In study 2, we carried out a cross-sectional analysis to examine the the clinical and biochemical 
profile associated with different definitions of the metabolic syndrome.  This study was an 
extension of study 2, in which we examined, in a prospective manner, the impact of these 
different definitions on the risk of  IHD.  The primary aim of this study was: 
1) To determine the impact of central obesity as an “essential” rather than “optional” 
component of the metabolic syndrome on the risk of IHD in a healthy Asian population  
 
Study 4  Insulin resistance is associated with a metabolic profile of altered protein 
metabolism in Chinese and Asian-Indian men 
1) to determine which of the elements of the metabolic profile associated with obesity is 
independently associated with IR?;   
2) When controlled for BMI, which metabolic features differ in the two ethnic groups living 
in Singapore?   
 
Study 5  Polymorphsism at the APOA1/C3/A4/A5 locus are associated with plasma lipids 
and modulate the association between obesity and dyslipdiemia in the Singapore 
Population. 
1)  To examine associations between polymorphisms at the APOA1/C3/A4/A5 locus and 
plasma lipids 
2) To explore the possibility that polymorphisms at this locus modulate the relationship 
between obesity and dyslipidemia 
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Chapter 3 STUDY POPULATIONS AND METHODS 
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3.1  Study populations 
The studies in this thesis utilized data from 4 previous cross-sectional studies in the Singapore 
population.  These were the thyroid heart study (THS), the National University Hospital Heart 
Study (NUHHS), the 1992 National Health Survey (NHS92) and the 1998 National Health Survey 
(NHS98).  These studies were combined based on the availability of the appropriate variables for 
the hypotheses that were tested in each population.  Subsequently, I was the principal 
investigator of a study that recalled all subjects from these 4 studies between 2003-2007.  This 
became known as the Singapore Prospective Study Program and provided additional data and 
materials for some of the studies performed as part of this thesis. 
 
3.1.1 Thyroid heart study (THS) 
We do not actually use data from this study in the studies that form part of this thesis.  This is 
because waist circumference, a key variable for the definition of the metabolic syndrome, was not 
measured as part of this study.  As such, while I will describe the sampling methodology, no 
details as to measurements made or other procedures will be described.  If required, these have 
been published84.  However, the study participants do form part of the sampling frame for the 
National University Hospital Heart Study and therefore, I felt it was important to describe the 
sampling methodology here. 
 
The THS used a four stage sampling design. In the first three stages, stratified systematic 
sampling was used to select census districts and then within these, reticulated units and 
households. The proportions of Malay and Indian households were increased to 25% and 15% 
respectively to increase statistical efficiency in comparing findings between ethnic groups. For the 
fourth stage, field officers visited the selected houses and listed persons aged 18 years and over, 
after which a random selection of these persons was made using a sampling fraction of between 
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0.5 and 0.67. Two attempts were made to persuade the persons to attend the clinic at Singapore 
General Hospital between 1982 and 1985. A final response of 2143 (60 3%) in persons aged 18 
to 69 years was obtained, with the response rates by ethnic group and sex being: Chinese males 
64.6%o, females 60.2%; Malay males 52.4%, females 52.1%; and Indian males 66.0%, females 
64.3%. Comparisons were made between the respondents, the sample, and the sampling frame, 
and no major discrepancies were found by age, sex, and ethnic group; the youngest age group 
had slightly lower response rates than the older ones.  
 
3.1.2  National University Hospital Heart Study (NUHHS) 
This cross sectional survey was .of a random sample of persons aged 30 to 69 years from the 
general population of Singapore. The sample was obtained from two sources-the Thyroid and 
heart study (described above) and electoral registers of  five divisions, each in a different part of 
the Singapore (north, south, east, west, and centre). There was disproportionate sampling in 
relation to ethnic groups to obtain equal numbers of subjects in each of the six gender-ethnic 
groups. The required sample was 180 subjects in each gender-ethnic group giving a total of 1080 
subjects. Assuming that 20% of the subjects would not be recruitable because of death, 
migration, infirmity, or relocation (which was high in Singapore at that time due to massive urban 
redevelopment), and assuming a response rate of 75%, a total of 1800 persons was selected. Of 
these, 419 (23.3%) were not recruitable and 983 responded, giving a response rate of71.2%. Of 
the 983 subjects, 22 were 70 years or over and were excluded, leaving 961 persons aged 
between 30 and 69 years.   
 
Morning clinics were held from June 1993 to December 1995, with both genders and three ethnic 
groups seen concurrently. Subjects were asked to fast from 21.00 hours the previous evening. 
Questionnaires were administered by a nurse trained in interview techniques with questions on 




Anthropometric measurements were carried out by a nurse trained in the techniques. Height (to 
the nearest 0.1 cm) and weight (to the nearest 0.1 kg) were measured on a SECA machine 
without shoes and in light clothing after emptying all pockets. Waist circumference (smallest 
measurement between the costal margins and the iliac crests) and hip circumference (at the level 
of the greater trochanters) were measured with a tape to the nearest 0.5 cm with the subject 
standing. Blood pressures were taken using the standard mercury sphygmomanometer. The 
same doctor  did the measuring to remove inter-observer variation, and it was carried out 
according to the MONICA project protocol85 to reduce intra-observer variation. Measurement took 
place between 09.00 and 11.00 hours to remove diurnal variation. Phases 1 and 5 were recorded 
and the mean of two readings used for the analyses.  
 
Venous blood samples were taken with the subject in a sitting position. Venepuncture took place 
between 10.00 and 12.00 hours to remove diurnal variation, and after at least 10 minutes rest. All 
measurements were made in the Department of Laboratory Medicine, National University 
Hospital, within 1 hour of collection. Lipids were measured enzymatically on an autoanalyser 
(Ektachem, Kodak)-total cholesterol and triglyceride directly and HDL cholesterol after 
precipitation, with LDL cholesterol calculated using the Friedewald formula. Plasma glucose was 
measured in blood collected in fluoride oxalate by a specific enzyme assay on the Kodak 
Analyser. Subjects with a glucose concentration > 5.5 mmol/l who were not currently on 
medication for diabetes subsequently had an oral glucose tolerance test (after at least 10 hours' 
fasting) of 75 g of dextrose in 296 ml of carbonated orange (Trutol 75, Custom Laboratories Inc, 
USA). They then had measurements of plasma glucose at fasting and 2 hours after the oral 
glucose. Those with a fasting plasma glucose concentration <5.5 mmol/l are very unlikely to have 
diabetes. Subjects currently taking medication for diabetes were also classified as diabetic.  
 
3.1.3  1992 National Health Survey (NHS92) 
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The NHS92 was conducted between September and November 1992 at six community centers 
distributed around Singapore Island. The survey team moved systematically each fortnight, 
through Silat, To a Payoh, Fengshan, Ang Mo Kio, Ulu Pandan, and Chong Pang community 
centers over the 3-month period, to provide island-wide coverage of survey sites and proximity to 
those selected. A total of 4,915 individuals were randomly selected from a sample of all 
household units in Singapore, obtained from the Department of Statistics’ National database on 
dwellings in Singapore. The characteristics of the selected sample conformed to that of the 
resident population. Systematic sampling, followed by disproportionate stratified sampling by 
ethnic groups, was used to select the sample for the survey. The two minority groups, Malays and 
Asian Indians, were oversampled to give an ethnic distribution of 60% Chinese, 20% Malays, and 
20% Asian Indians. This was to ensure sufficient numbers for statistical analysis, and 
representative results were weighted back during the analysis of findings. From the 4,915 eligible 
individuals randomly selected from a sample of all household units in Singapore, 3,568 Singapore 
residents aged between 18 and 69 years finally participated in the survey.  The response rate 
was 72.6%. Although response rates did differ between ethnic groups, the non responders were 
contacted and information was sought regarding their demographic and socioeconomic profile 
and diabetes and hypertension status. This was to ensure that the prevalence of these diseases 
would not be underestimated during the survey. Characteristics of the non-responders were 
similar to those of the survey respondents. 
 
The protocols and procedures used in the NHS ’92 were based on the 1990 Mauritius Non-
communicable Diseases Survey 86 and the World Health Organization’s Monitor Trends in 
Cardiovascular Diseases protocol 87. An interviewer-administered questionnaire was used to 
capture data on socio-demographic factors, dietary intake, physical activity, smoking and alcohol 
consumption.  
 
All biochemistry analyses were done at the biochemistry Laboratory of the Singapore General 
Hospital, which is accredited by World Health Organization International Quality Assurance 
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programs and the College of American Pathologists program . Fasting blood specimens for lipids 
(10 ml plain tubes), and glucose (2 ml fluoride oxalate tubes) were taken from all respondents 
after an overnight fast of 10 h. All subjects (1,315 men and 1,426 women) except those with 
diabetes on oral hypoglycemic medications or insulin were then given an oral glucose tolerance 
test (OGTT) (75 g of anhydrous glucose made up to 250 ml of solution with water). All blood 
specimens were centrifuged at room temperature (27–30ºC) on-site to separate the sera, which 
were then placed in separate tubes on ice for daily dispatch to the central biochemistry 
laboratory. Plasma glucose and lipid measurements were performed on the same day as 
collection. Glucose measurements were done by the glucose oxidase method using the Vitros 
700 Chemistry Analyzer (Rochester, NY), with an intra-assay coefficient of variation (CV) of 1.2% 
and an interassay CV of 1.5%. Total cholesterol (intra-assay CV 3.0% and interassay CV 4.1%) 
and triglyceride (TG) (intra-assay CV 1.4% and interassay CV 1.9%) were measured directly by 
enzymatic methods using Kodak Ektachem clinical chemistry slides. HDL cholesterol (intra-assay 
CV 2.6% and interassay CV 4.4%) was separated from LDL and VLDL by precipitation with 
dextran sulfate and magnesium chloride and then measured by enzymatic methods as in 
cholesterol measurements. The slides were then read on the Vitros 700 Chemistry Analyzer. LDL 
cholesterol was calculated by Friedewald’s equation.  
 
Height (to the nearest millimeter) was recorded in all subjects without shoes, and weight (in 
kilograms) was measured in subjects in light clothing using electronic weighing scales (SECA 
model 220). Waist (defined as the narrowest part of the body below the costal margin) was 
measured using a non-elastic tape measure. At least two readings of blood pressure were taken 
from respondents who had rested adequately before measurement, using a standard mercury 
sphygmomanometer. If the two readings differed by more than diastolic 15 mmHg or systolic 25 
mmHg, a third reading was performed. The mean values of the closest two readings were 
calculated.  
 
3.1.4  1998 National Health Survey (NHS98) 
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NHS98 was a cross-sectional study conducted between September amd November 1998 through 
six survey centers across the Singapore Island.  To ensure comparability of the data with that 
obtained from NHS92, almost identical methodology was employed.  A target sample size of 
5000 subjects was determined in order to have 80% power to detect a 10-15% difference in the 
prevalence of common diseases and risk factors.  The sampling was divided into 2 phases.  In 
the first phase, to account for non-respondents, 11,200 households were selected from the 
National Database on Dwellings.  These households were selected based on their proximity to 
the six survey centers as well as based on house-type (as a proxy for socio-economic status 
(SES) to ensure a representative distribution of households in Singapore.  In the second phase, a 
random sample of 7500 individuals (between ages 18-69 years) were selected from the 11,200 
households, with an oversampling of Malays and Asian-Indians to ensure that prevalence 
estimates for these ethnic groups were reliable.    Participants were contacted first by mail, then 
by telephone. Interviewers subsequently also conducted a home visit.    A response rate of 64.5% 
(4723/7500) was achieved comprising 3228 Chinese (64%), 849 Malays (21%) and 646 Asian-
Indians (15%). 
 
Fasting blood samples were drawn for measurement of glucose and lipids in all subjects in after a 
10 hour overnight fast.  As in the NHS92, the tubes were centrifuged on site and then sent to the 
Biochemistry Laboratory (Department of Pathology, Singapore General Hospital) for analysis on 
the same day. Serum lipid and glucose concentrations were measured using kits from Boehringer 
Mannheim Systems (Mannheim, Germany) and read on a BM/Hitachi 747 analyzer (Roche 
Diagnostics, Corp. Indianapolis, IN). Total cholesterol [intra-assay coefficient of variation (CV) 
0.8%, interassay CV 1.7%], triglyceride (intra-assay CV 1.5%, interassay CV 1.8%) and glucose 
(intra-assay CV 0.9%, interassay CV 1.8%) were measured using enzymatic colorimetric assays. 
HDL-C (intra-assay CV 2.9%, interassay CV 3.6%) was measured using a homogenous 
colorimetric assay, whereas low-density lipoprotein cholesterol (LDL-C) (intra-assay CV 0.9%, 
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interassay CV 2.0%) was measured using a homogenous turbidimetric assay. Insulin levels were 
measured using immunoassay (Abbott ASYM Abbott Laboratories, Chicago, IL).   
 
Height (to the nearest millimeter) was recorded in all subjects without shoes, and weight (in 
kilograms) was measured in subjects in light clothing using electronic weighing scales (SECA 
model 220). Waist (defined as the narrowest part of the body below the costal margin) was 
measured using a non-elastic tape measure. At least two readings of blood pressure were taken 
from respondents who had rested adequately before measurement, using a standard mercury 
sphygmomanometer. If the two readings differed by more than diastolic 15 mmHg or systolic 25 
mmHg, a third reading was performed. The mean values of the closest two readings were 
calculated.  
 
DNA was isolated from blood samples using DNA blood Midi kits (Qiagen, Hilden, Germany) 
following the manufacturer’s recommended protocol.  DNA samples for 2936 Chinese, 788 
Malays and 598 Asian-Indians were available for analysis. 
 
3.1.5 The Singapore Prospective Study Program (SP2) 
Between 2004 and 2007, I was the principal investigator of this study which invited 10,445 
subjects from all four studies described above (the THS, the NUHHS, NHS92 and NHS98) to 
participate in a repeat examination.  Subjects deceased at the time of follow-up (as shown by 
data linkage to the Registry of Births and Deaths) were excluded (n- 517). Also excluded were 6 
subjects who had emigrated and 85 who had errors in the records regarding their identity card 




Subjects were contacted to obtain an appointment for investigators to administer the 
questionnaire at a subject’s home. Three home visits were made on 3 different occasions, 
including one weekend and weekday, before a subject was deemed non-contactable. After this 
procedure was completed, 2,673 subjects were non-contactable. Of those subjects who could be 
contacted, 30 (0.3%) refused to participate. All subjects were invited to attend a health 
examination for additional tests and collection of biologic specimens shortly after the home visit. A 
total of 7,742 (74.1% response rate) subjects completed the questionnaire; 5,157 of them (66.6% 
of those who completed the questionnaire or 49.4% of all eligible subjects) also attended the 
health examination (Figure 3). Ethics approval was obtained from 2 institutional review boards 
(the National University of Singapore and the Singapore General Hospital). Informed consent was 




Figure 3.  Subject recruitment for the Singapore Prospective Study Program 
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Data on demographic and lifestyle factors (alcohol consumption, smoking), as well as medical 
history (including physician-diagnosed hypertension, diabetes mellitus, and hyperlipidemia), were 
collected by using interviewer administered questionnaires. For the health examination, 
participants were examined the morning following a 10-hour overnight fast. Venous blood was 
drawn and collected in plain and fluoride oxalate tubes and was stored at 4oC for a maximum of 4 
hours prior to processing. A random urine specimen was also collected. All biochemical analyses 
of blood were carried out at the National University Hospital Referral Laboratory, which is 
accredited by the College of American Pathologists. Serum total cholesterol, triglyceride, and high 
density lipoprotein cholesterol were measured by using an automated autoanalyzer (ADVIA 2400; 
Bayer Diagnostics, Tarrytown, New York). Low density lipoprotein cholesterol levels were 
calculated by using the Friedewald formula. Plasma glucose was also assayed with enzymatic 
methods (ADVIA 2400) by using blood collected in fluoride oxalate tubes. The intraday and 
interday coefficients of variation for total cholesterol, triglyceride, high density lipoprotein 
cholesterol, plasma glucose were 0.80%–1.57% and 0.93%– 1.15%, 0%–3.85% and 1.27%–
3.40%, 0.56%–0.65% and 1.18%–2.00%, and 0%–0.93% and 1.68%–1.83%, respectively. 
Random urinary creatinine was measured by using a commercial assay (Immulite; Diagnostic 
Products Corporation, Gwynedd, United Kingdom for urinary albumin and Roche Diagnostics 
GmbH, Mannheim, Germany for creatinine). The lower detection limits for urinary creatinine was 
0.027 mmol/l. 
 
Height was measured without shoes by using a wallmounted stadiometer. Weight was measured 
in light clothing by using the same digital scale (SECA, model 782-2321009; Vogel & Halke, 
Hamberg, Germany) for all participants. Participants were instructed to remove any objects such 
as keys and mobile phones before measurement. An automated blood pressure monitor 
(Dinamap Pro100V2; Criticon, Norderstedt, Germany) was used to take 2 blood pressure 
readings from participants after 5 minutes of rest. A third reading was performed if the difference 
between the 2 readings of systolic blood pressure was greater than 10 mm Hg or of diastolic 
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blood pressure was greater than 5 mm Hg. Mean values of the closest 2 readings were 
calculated. The respective inter- and intra- observer coefficients of variation for systolic blood 
pressure were 0.51%–10.20% and 0%–2.5%, whereas they were 0.41%– 7.50% and 0%–2.5% 









3.2 SPECIFIC DESIGN AND METHODS FOR STUDIES 
 
3.2.1 Study 1 
Study 1 was a cohort study.  We combined the individuals who participated in the NUHHS and 
the NHS92 as illustrated in figure 4.  Outcomes were obtained by linking individual records (using 
unique national registry identity card numbers) to three national registries as previously described 
88, 89. These were: (i) the Registry of Births and Deaths; (ii) the Central Claims Processing System 
and its predecessor the Hospital Inpatient Discharge System. These databases capture inpatient 
discharge information from all hospitals in Singapore, both public and private; (iii) the Singapore 
Myocardial Infarct Registry, a population based registry with comprehensive coverage of acute 
myocardial infarction occurring in Singapore. All obtained outcome measures were in coded form 
using the Ninth Revision of the International Classification of Diseases (ICD-9). An IHD event was 
defined as the occurrence of acute myocardial infarction or IHD (ICD-9 410-414) recorded in the 
aforementioned registries. The first IHD event was used for analysis.  Subjects were censored as 





Figure 4.  Establishing a cohort for studies 1 and 3. 
 
This analysis included 3954 subjects (3156 from the 1992 National Health Survey and 798 from 
the National University of Singapore Heart Study). We excluded 367 subjects with diabetes 
mellitus, 61 subjects with pre-existing IHD and 31 subjects with both. A further 27 subjects were 
excluded in this analysis due to missing data in the fields used.  
 
The presence of three out of five of the following criteria constituted a diagnosis of the MS in 
accordance with the NCEP ATP III recommendations90: 
1) WC> 102 cm in men or 88 cm in women;  
2)  fasting TG≥1.7 mmol/l;  
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3) HDL-C < 1.0 mmol/l in men or <1.3 mmol/l in women;  
4) blood pressure≥130/85mmHg or hypertensive on medication; 
5)  fasting glucose≥6.0 mmol/l.  
 
For the modified Asian criteria, we used a waist circumference of 90 cm in men and 80 cm 
inwomen to define central obesity 31. The other criteria were unchanged. Diabetes mellitus was 
diagnosed in those with fasting plasma glucose >7.0 mmol/l or if the study subject gave a history 
of diabetes mellitus for which they were receiving treatment in the form of oral hypoglycemic 
agents or insulin.  
 
Statistical analysis  
Statistical analyses were performed using SPSS version 11.2 for windows (SPSS Inc. Chicago, 
IL). Continuous variables were expressed as means with standard deviation in parenthesis. 
Categorical variables are expressed in percentages. Time-to-event analyses were conducted 
using Cox proportional hazards regression (stratified by the study from which the data was 
derived). This allowed the baseline hazard function to differ for subjects from each of the two 
studies in order to take into account any period effects on IHD incidence. Hazard ratios (HR) and 
95% confidence intervals (95% CI) for IHD amongst those who satsfied only the Asian criteria for 
MS and those who satisfied both the Asian and the NCEP ATP III criteria compared to those who 
satisfied neither set of criteria were estimated. We first conducted the analyses separately for 
men and women and in each ethnic group (Chinese, Malay and Asian Indian). The patterns of 
associations were similar (although some failed to reach statistical significance due to the small 
number of events in some groups). We also tested for homogeneity of effect by including the 
interaction term MS×gender and MS×ethnic group in the model. Neither of these terms were 
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statistically significant (p = 0.555 for gender and p = 0.863 for ethnic group). As such, men and 
women from all three ethnic groups were combined and analyses were carried out after 
adjustment for age, sex, ethnicity and current cigarette smoking.  
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3.2.2  Study 2 
This study was a cross-sectional study and utilized data from the NHS98.  By the time this study 
was carried out, the IDF22 and AHA/NHLBI21 had adopted the definition of central obesity used in 
study 1 as part of their recommendations for defining the metabolic syndrome in persons of Asian 
ethnicity.  Furthermore, both groups included individuals with diabetes mellitus in the definition.   
 
Each individual was categorized according to the five criteria for the metablic syndrome 21, 22 
1) elevated triglycerides: ≥150 mg/dl (1.7 mmol/l); 
2) reduced HDL cholesterol: < 40 mg/dl (1.03 mmol/l) in male subjects and < 50 mg/dl (1.29 
mmol/l) in female subjects; 
3) elevated blood pressure: systolic ≥130 mmHg or diastolic ≥85 mmHg or on treatment for 
hypertension; 
4) elevated fasting plasma glucose: ≥100 mg/dl (5.6 mmol/l) or on treatment for type 2 
diabetes; and  
5) central obesity, using the waist circumference for South Asians/Asians: >90 cm in male 
subjects and >80 cm in female subjects. 
 
The population was then divided into four mutually exclusive groups according to the presence of 
central obesity and the presence of multiple other features of MS. Group 1 comprised those 
individuals without central obesity and who exhibited two or fewer of the other risk factors. Group 
2 comprised those individuals with central obesity but who exhibited none or one of the other risk 
factors. Group 3 comprised those individuals who exhibited three or more risk factors, of which 
central obesity was not one. These individuals would be classified as having MS by the AHA/ 
NHLBI criteria but not by the IDF criteria. Group 4 comprised those individuals who exhibited 
central obesity and at least two other risk factors. These individuals would be classified as having 




Insulin resistance was calculated using homeostasis model assessment.  Insulin resistance were 
estimated using the Homeostatic Model of Assessment (HOMA) as described by Matthews et 
al91.  These estimates have been demonstrated to correlate with the ‘gold-standard’ measures for 
insulin resistance (euglycaemic clamp) and β-cell function (hyperglycaemic clamp).  The 
estimates were calculated using the formulae:  HOMA-IR = Fasting plasma glucose (mmol/L) x 
Fasting insulin (μU/ml) ÷ 22.5. 
 
Using the Framingham risk score based on LDL-C level 13, we calculated the estimated total 
coronary heart disease risk over a 10-year period for every individual included in the analysis. 
 
Statistical analysis 
 Statistical analyses were performed with SPSS/PC statistical program (version 11.5 for 
Windows; SPSS, Inc., Chicago, IL). Values are expressed as means ± standard deviation. The 
differences in clinical characteristics and body composition among the groups were compared 
using ANOVA. TG and insulin resistance were log-transformed to improve the skewness of the 
distribution. Subsequently, their means were back-transformed for presentation in the tables. Post 
hoc analyses were carried out using a Bonferroni correction. All proportions were compared using 
the Chi-square2 test. P< 0.05 was considered statistically significant. To compare proportions 
after adjustment for age, we utilized multinomial logistic regression.  
58 
 
3.2.3  Study 3 
This study was a cohort study and utilized the same study population and dataset as study 1.  
 
The central obesity/metabolic syndrome status of individuals was obtained using the criteria set 
out by IDF 22 and AHA/ NHLBI 21:  
1) elevated triglycerides: ≥150 mg/dl (1.7 mmol/l); 
2) reduced HDL cholesterol: < 40 mg/dl (1.03 mmol/l) in male subjects and < 50 mg/dl (1.29 
mmol/l) in female subjects; 
3) elevated blood pressure: systolic ≥130 mmHg or diastolic ≥85 mmHg or on treatment for 
hypertension; 
4) elevated fasting plasma glucose: ≥100 mg/dl (5.6 mmol/l) or on treatment for type 2 
diabetes; and  
5) central obesity, using the waist circumference for South Asians/Asians: >90 cm in male 
subjects and >80 cm in female subjects. 
 
Using these five metabolic score components, individuals were categorized into three central 
obesity/metabolic syndrome groups: 1) no metabolic syndrome, which includes individuals with 
less than three metabolic syndrome components; 2) central obesity and metabolic syndrome, 
which includes individuals with elevated waist circumference and two or more other components; 
and 3) no central obesity and metabolic syndrome, which includes individuals with low waist 
circumference but three or more other components.  
 
Statistical analyses 
Statistical analyses were performed using SPSS (version release 13.0.1, 2004; Chicago, IL). 
Categorical variables were expressed in percentages and continuous variables in means ± SD 
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unless otherwise specified. Incidence rates for first IHD events were calculated for each of the 
central obesity/ metabolic syndrome groups, and Cox proportional hazards regression was used 
to obtain adjusted hazard ratios (HRs) for first IHD events. The time-to-IHD event was the 
difference between the date of the first IHD event and the date of entry into the study. Subjects 
without IHD were censored at 31 December 2002 or the date of non-IHD death, whichever 
occurred first. HRs were adjusted for age, sex, ethnic group, study, LDL cholesterol, smoking, 
and alcohol intake. Interaction terms, created using the three central obesity/ metabolic syndrome 
groups, with ethnic group (P = 0.387), sex (P = 0.911), and study (P = 0.081) showed no 
significant interaction; thus, the analysis was done with ethnic group, sex, and study combined. 
An interaction term consisting of follow- up time and the three central obesity/ metabolic 
syndrome groups was used to test the proportional hazards assumption (15) for occurrence of 
IHD events and was found not to be significant (P = 0.351), indicating proportional hazard over 
time. The attributable percent among those with metabolic syndrome (APE: the percent of risk 
IHD among those with metabolic syndrome that is due to metabolic syndrome) and attributable 
percent among the total population (APT: that is the percent of risk of IHD among the whole 
population that is due to the metabolic syndrome) was also calculated for both AHA/NHLBI and 




3.2.4 Study 4 
This study was a case-control study. We selected a subset of individuals who participated in SP2.   
In this study, we chose to study men only, in order to reduce the potential confounding effects of 
gender as well as metabolic alterations occurring at different phases of the menstrual cycle.  
Furthermore, we chose to study only Chinese and Asian Indian men, as these were the ethnic 
groups that show the greatest differences in IR in our population 92, 93.  In order to examine the 
metabolic and hormonal correlates of IR as opposed to obesity, we first separated Asian Indian 
and Chinese men into the upper and lower tertiles of IR, as measured by homeostasis model 
assessment (HOMA)91.  These opposing tertiles corresponded to HOMA indices of ≤1.06 and 
HOMA ≥ 1.93.  We next excluded all those individuals who were taking medications for diabetes 
or hyperlipidemia, those who did not provide a urine specimen, and those with missing height and 
weight information.  This left 1042 men (56 Asian Indians with low HOMA, 132 Asian Indians with 
high HOMA, 547 Chinese with low HOMA and 307 Chinese with high HOMA).  Of the 56 Asian 
Indians with low HOMA index, 30 had BMI between 21 and 29 kg/m2 (non-obese).  For each of 
these 30 subjects, up to a maximum of 3 subjects with BMI within 0.3 kg/m2 were selected from 
each of the other 3 categories.  The final study subjects comprise of 30 Indians with low HOMA, 
53 Indians with high HOMA, 97 Chinese with low HOMA and 83 Chinese with high HOMA, giving 
a total sample size of 263 men. Results from analysis of metabolites in plasma were available on 
all 263 men. As for urinary analysis, 5 men had urine samples which were too dilute (<1.5µmol 
creatinine/mL) and therefore urinary analysis results were only carried out in 258 men.  
 
Assessment of physical activity 
Physical activity was assessed by interviewer-administered questionnaire with a recall period of 
the previous 3 months. The questionnaire was adapted from several sources94-97 and covered 
transportation, occupation, leisure time and household activities. A metabolic equivalent of task 
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(MET) value was assigned to each reported activity according to the compendium by Ainsworth 
et al 98, 99.  
Weekly energy expenditure in physical activity (Kcal/ week) was computed as: Hours spent on 
activity per day x numbers of day per week x METS x Body weight in kg. The energy 
expenditure for transportation, household and leisure time activity was calculated from light, 
moderate and vigorous activity whereas energy expenditure for occupation activity was from 
moderate and vigorous activity. 
Transportation activity: The questions on transportation activity were adapted from National 
Health Survey 2004 questionnaire100. To assess transportation activity, participants were asked 
about their involvement in active transportation (i.e. walking or cycling for transport at least 10 
minutes).  In addition, the duration, frequency and the intensity of the activity were also recorded. 
The intensity was assessed by asking the participants whether the intensity of walking or cycling 
was light, moderate or vigorous.  
 
Occupational activity: Questions on occupational activity were based on the previously validated 
Modifiable activity questionnaire 96 which was designed for the use in different populations 101. 
For occupational activity, individuals were asked to list all jobs held during the past 3 months. 
For each job entry, data was collected for the average job schedule (number of weeks in the last 3 
months, days per week, and hours per day worked). Activity on the job was determined by the 
number of hours spent sitting at work and the most common physical activities performed when 
not sitting, which were categorized into light, moderate and vigorous activity. Light activities 
include job activities involving standing still without heavy lifting, occasional short distance 
walking, general office work and similar activities. Moderate activities include continuous 
walking, carrying light loads and heavy cleaning, etc while vigorous activities include all those 
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activities with energy demands approaching those of heavy lifting, construction, etc. 4 METs and 
7 METs were assigned to moderate and vigorous activity respectively and no credit was given to 
light activity.   
Leisure time activity: The leisure time activity component was adapted from the Minnesota 
leisure time activity questionnaire which has been validated and evaluated against other physical 
activity questionnaires, accelerometers, fitness tests, and criterion methods on adults 102-109. The 
leisure time activities were grouped into four general categories: walking and miscellaneous (i.e 
bicycling, hiking, etc), conditioning exercise (ie, home exercise, health club exercise, jogging, 
running, etc), water activities (i.e water skiing, swimming, sailing, etc) and sports (i.e. bowling, 
tennis, soccer, etc) and covered 48 popular activities. The participants were asked if they 
performed any of the activities under these four categories or any other leisure time activities 
during the past 3 months. For each activity, participants identified the frequency per week/ month 
and the average minutes of participation in each activity for each time.   
Household activity: The household activity component was adapted from the validated Yale 
physical activity questionnaire, which has been shown to be acceptable and reliable 94, 110-112.  
Three categories of common household activities were covered in this section: housework, yard 
work and caretaking (elderly persons or children). Participants were asked the type of activity 
performed, the frequency (the number of times per week), and the duration (length of time spent 
in the activity per day).  
 
 
Biochemical measurements.   
For this study, in addition to the biochemical measurements that have already been described, a 
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panel of metabolic, hormonal, and inflammatory marker assays were performed at the Sarah W. 
Stedman Nutrition and Metabolism Center, Duke University.  Commercial radioimmunoassays 
were used to measure leptin (Millipore, St. Charles, MO) and total insulin-like growth factor-I 
(IGF-I, Beckman-Coulter, Webster, TX).   Searchlight chemiluminescent technology (Thermo 
Pierce-Endogen, Woburn, MA) was used for measuring three IGF-1 binding proteins (IGFBP1, 
IGFBP2, IGFBP3) using a custom multiplex assay.  Adiponectin was measured via technology 
from Meso Scale Discovery (MSD, Gaithersburg, MD), as was a 9-plex cytokine panel for GM-
CSF, IFN-γ, IL-10, IL-12p70, IL-1β, IL-2, IL-6, IL-8, and TNFβ.   Total free fatty acids, ketones and 
3-hydroxybutyrate (reagents from Wako, Richmond, VA) and lactate (Roche, Indianapolis, IN) 
were measured on a Hitachi 911 autoanalyzer. 
 
Acylcarnitines and amino acids were analyzed in plasma by tandem mass spectrometry (MS/MS), 
and urine organic acids by gas chromatography/mass spectrometry (GC/MS) as described 
previously 58, 113-117.  All MS analyses employed stable-isotope-dilution with internal standards 
from Isotec (St. Louis, MO), Cambridge Isotope Laboratories (Andover, MA), and CDN Isotopes 
(Pointe-Claire, Quebec, CN).  A list of all internal standards utilized in these studies has been 
published 114.  
 
Characteristics and performance of the assays have been previously published 118.  In general, 
the assays that were used in this study gave coefficients of variantion <10% for hormones and 
cytokines, <5% for the conventional metabolites measured on the Hitachi 911 autoanalyser, and 




Ethics approval was obtained from two Institutional Review Boards (National University of 
Singapore and Singapore General Hospital). Informed consent was obtained before conduct of 
study. 
 
Statistical analyses.   
Statistical analysis was carried out using STATA (StataCorp LP, College Station, Texas, USA).  
Categorical variables were compared using the chi-square test.  Continuous variables were 
compared using analysis of variance.  We first used an F-test to identify those variables for which 
at least 1 of the 4 groups showed a statistically significant difference from the others.  
Subsequently, the levels of metabolites in high and low HOMA groups were compared using 
analysis of covariance, with and without adjustment for age and BMI.  A p-value < 0.05 was taken 




3.2.5  Study 5 
This study was a cross sectional study and  utilized data and DNA from the NHS98.  For the 




Genotyping was carried out at different times for the 4 loci examined in this study.  As such, the 
methods differed somewhat. 
 
APOA5 
Genotyping at the APOA5 locus was carried out as previously described119.  Briefly, we identified 
12 SNPs on the National Center for Biotechnology Information Human SNP Database and tested 
their informativeness in these ethnic groups on a pilot experiment including 278 subjects (i.e., 
three 96-well plates of DNA samples including 147 Chinese, 93 Malays, and 38 Asian- Indians). 
Based on this study, five of the SNPs were either monomorphic or had average frequencies of 
the minor allele of < 0.05 in our population, and Three other SNPs (ss4383598, ss2990302, and 
ss1943494) were not given further consideration, because of their low reliability for genotyping 
across all three populations.   At the end, five previously reported SNPs 79, 120, 121were included for 
the analyses presented in this research.  Subsequently, we genotyped an additional SNP 82 which 







18 SNPs were selected from the dbSNP, which comprised all SNPs validated by frequency at the 
time of the selection on 16 April 2004.  Genotyping for all 18 SNPs was performed in an initial 
sample of 517 individuals comprising 367 Chinese, 80 Malay and 70 Indians.  Of the 18 SNPs, 
four did not display any variability, and variation in SNP rs5135 was seen in one heterozygous 
individual.  These SNPs were not evaluated further.  We then examined the patterns of linkage 
disequilibrium between these SNPs using Haploview122.  The pattern of R2 across the locus is 
shown in Figure 1.  Based on these data, to increase the efficiency of genotyping, tagSNPs were 
selected using pairwise tagging R2 between the remaining 13 SNPs.  Using a tagging R2 cut-off of 
0.80, two SNPs (rs5142 & rs5141) were found to be in strong LD with rs5128.  Although 
rs33989105 and rs35523410 (also known as -482 and -455 respectively) showed a high degree 
of LD, both SNPs were included due to previous data suggesting that these were functional. On 
this basis, we selected 11 SNPs to be genotyped in our population.    Five DNA fragments 
encompassing all 18 polymorphisms were amplified in a single multiplex polymerase chain 
reaction and genotyping was carried out using the ABI Prism SNaPshot multiplex system (Applied 
Biosystems, Foster City, CA). 
 
APOA1 and APOA4 
For these 2 loci, we selected SNPS from dbSNP as we had done for APOC3.  However, 
genotyping of SNPs at these loci were carried out using the Sequenom MassARRAY platform 
(Sequenom, San Diego, CA, USA) without selection.   
 
Statistical Analysis 
To study the association between serum lipid concentrations and the individual SNPs, we used 
linear regression models under various inheritance models (additive, dominant and recessive).  
The serum lipid concentrations investigated were total cholesterol (TC), TG, HDL-C and LDL-C.  
To test for interactions between genetic variants and obesity, the interaction term SNPXBMI was 
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introduced into the model.  To account for multiple testing, we used Bonferroni corrections and 




Chapter 4 RESULTS  
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4.1  Study 1: The impact of modifying the definition of central obesity in Asian populations 
on the association between the metabolic syndrome and ischemic heart disease 
 
Table 3 shows the baseline characteristics of the subjects included in this analysis.  
 
Table 3.  Baseline characteristics (mean±SD) of non-diabetic participants from the 1992 National 
Health Survey and the National University of Singapore Heart Study. 
  Male 
(n = 1905) 
Female 
(n = 2049) 
Age (years)  38.6 (13.0) 38.9 (12.3) 
Waist (cm)  80.5 (10.4) 72.3 (10.7) 
BMI (kg/m2)  23.2 (3.8) 23.3 (4.6) 
Total cholesterol (mmol/l)  5.35 (1.04) 5.31 (1.03) 
Triglyceride (mmol/l)  1.65 (1.62) 1.20 (0.77) 
HDL cholesterol (mmol/l)  1.08(0.29) 1.31 (0.35) 
LDL cholesterol (mmol/l)  3.57 (0.94) 3.46 (0.96) 
Ethnic group (%) Chinese 59.7% 60.9% 
 Malay 21.3% 20.1% 
 Asian Indian 19.1% 19.1% 
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*Hypertension (%)  10.6% 8.2% 
Current smokers (%)  35.2% 2.8% 
 
*Hypertension was diagnosed if blood pressure >140/90 mmHg or the subject was gave a history 
of treatment with anti-hypertensive medication.  A subject was considered a current smoker if 
he/she smoked daily. 
 
 Table 4 shows the prevalence of the individual features of the MS using both the NCEP ATPIII 
criteria and the modified Asian criteria.  The lowering of the cut-off for waist circumference led to 
an increase in the prevalence of central obesity from 2.8% to 17.1% in men and 8.7% to 21.8% in 
women.  Correspondingly, the prevalence of the MS defined by the modified Asian criteria rose 




Table 4.  Prevalence [percentages (95% CI)] of features of the metabolic syndrome amongst non-
diabetic participants of the 1992 National Health Survey and the National University of Singapore 
Heart Study according to the NCEP ATP III criteria and the modified Asian criteria.  
 Male 
(n = 1905) 
Female 
(n = 2049) 
TG≥1.7 mmol/l 32.9 (30.8 - 35.0) 16.8 (15.3 - 18.5) 
Low HDL-C (<1.0 mmol/l in men and <1.3 
mmol/l in women) 
46.9 (44.7 – 49.2) 51.3 (49.1 – 53.5) 
Fasting plasma glucose >=6.0 mmol/l 8.7 (7.5 - 10.1) 7.2 (6.2 - 8.4) 
BP≥130/85 mmHg or hypertensive on 
treatment 
29.6 (27.6 - 31.7) 23.0 (21.2 – 24.9) 
Central obesity (NCEP Criteria) 2.8 (2.1 - 3.6) 8.7 (7.6 - 10.0) 
Central obesity (Asian Criteria) 17.1 (15.4 - 18.8) 21.8 (20.1 – 23.7) 
Metabolic syndrome (NCEP ATP III criteria) 14.1 (12.6 - 15.8) 12.3 (11.0 – 13.8) 
Metabolic syndrome (modified Asian Criteria) 19.2 (17.5 – 21.0) 16.4 (14.9 - 18.1) 
 
We subsequently divided the study population into those without the MS, those who satisfied only 
the Asian criteria for MS and those who satisfied both the Asian and the NCEP criteria.  After 
38,157.4 person years of follow up amongst subjects with neither diabetes mellitus nor IHD at 
baseline, an incident IHD event occurred in 93 subjects.  The MS was associated with step-wise 
increase in the risk of IHD beginning with those who satisfied the modified Asian criteria only to 
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Figure 5.  Survival curves for subject who satisfied the NCEP ATP III criteria for the metabolic 
syndrome (MS NCEP), the modified Asian Criteria (MS Asian) and neither (No MS) in relation to 
ischemic heart disease.  Analyses were carried out using Kaplan Meier analysis. 
 
 
These associations were observed even after adjustment for age, sex, ethnic group, current 
cigarette smoking (table 5) with adjusted hazard ratios of  2.13 (95% CI 0.99-4.58) and 3.09 (95% 
CI:  1.96-4.88) respectively for the modified Asian Criteria alone and the NCEP ATP III criteria.  
Additional adjustment for serum low density lipoprotein cholesterol concentration did not alter the 
findings (data not shown). 
 
Table 5.  Risk of Ischemic Heart Disease Events associated with the metabolic syndrome 
amongst non-diabetic participants of the 1992 National Health Survey and the National University 
of Singapore Heart Study according to the NCEP ATP III criteria and the modified Asian criteria.  
Hazard ratios were estimated using Cox proportional hazard’s regression (stratified by the study 
from which the data was derived) and adjusted for age, gender, ethnic group and current 
cigarette smoking. 




95% CI p-value 
No metabolic 
syndrome 
32064.8 42 1.00 - - 
Metabolic syndrome-
Asian criteria only 
1565.9 8 2.13 0.99,4.58 0.052 
Metabolic syndrome 
(NCEP ATP III 
criteria) 
4526.7 43 3.09 1.96,4.88 <0.005 





When each set of criteria were applied separately, the hazard ratio for IHD associated with the 
MS diagnosed according to the Asian criteria was 2.87 (95% CI 1.85-4.44) and that according to 
the NCEP ATP III criteria was 2.78 (95% CI 1.80-4.31).  Based on these hazard ratios and the 
prevalence of the MS according to each set of criteria found in Table 3, the population attributable 
risk (PAR) associated with the MS when the Asian criteria are applied is  24.4%.  The PAR 
associated with the MS when the NCEP ATP III criteria are applied is 18.8%.  Use of the Asian 
criteria, as opposed to the NCEP ATP III criteria, to define the MS resulted in an increase in 





4.2  The role of central obesity in the definition the metabolic syndrome 
4.2.1  Study 2:  Impact on associations with insulin resistance 
Table 6 shows the prevalence of each of the individual features of the metabolic syndrome by 
gender and ethnic group.   
 
Table 6.  Prevalence of individual features of the metabolic syndrome by gender and ethnic 
group.  The 1998 Singapore National Health Survey. 
Metabolic features Men Women 
 
Chinese Malay Asian 
Indian 
Chinese Malay Asian 
Indian 
 n=1467 n=403 n=307 n=1756 n=445 n=337 
 % % % % % % 
Waist circumference >90 
cm in men or >80 cm in 
women 
25.4 32.0 44.6 18.9 43.4 56.4 
Fasting plasma glucose 
>=5.6 mmol/l or 
treatment for diabetes 
mellitus. 
48.5 56.6 56.0 29.9 46.7 44.5 
Systolic blood pressure 
>=130 mmHg or diastolic 
blood pressure >= 85 
mmHg or treatment for 
hypertension 
36.5 39.7 37.1 20.4 35.5 21.7 
Fasting triglyceride >1.7 
mmol/l 
34.6 45.2 48.5 14.5 24.7 21.1 
High density lipoprotein 
cholesterol < 1.0 mmol/l 
in  men or 1.3 mmol/l in 
women 
20.7 33.0 45.9 23.9 36.2 65.6 
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The prevalence of the metabolic syndrome defined according to the recommendations of the IDF was 
20.2% and that defined by the AHA/NHLBI recommendations was 26.9%.  6.7 percent of the population 
who did not meet the criteria for central obesity exhibited three or more features of the metabolic 
syndrome.   
 
Table 7 shows these prevalences by gender and ethnic group.  The p-values for the differences in 
proportions of each group by ethnicity was highly statistically significant (p<0.005) both before and after 
adjustment for age.  A greater proportion of Asian Indians exhibited three or more features of the MS 
which included central obesity.  This was observed in both men and women.  In contrast, more Malays 
exhibited three or more risk factors without central obesity.  This phenotype was more common in men 
than in women.  The degree of discordance between the AHA/NHLBI and the IDF criteria was greater in 
Chinese and Malay men than Asian Indian men (p=0.023 after age adjustment) and in Chinese than 
Malay and Asian Indian women (p<0.005 after age adjustment). 
 
Table 8 shows the insulin resistance, and other phenotypic characteristics associated with the four 
mutually exclusive groups defined in the methods section of this manuscript.  Individuals in group 3 (≥3 
risk factors without central obesity) were indistinguishable from those in group 4 (≥3 risk factors including 
central obesity) in relation to age, blood pressure, total cholesterol and LDL-cholesterol.  However, the 
latter had higher fasting glucose and insulin resistance and were more likely to have diabetes mellitus.  
They also had lower TG and higher HDL-C compared to those in group 3.  The Framingham risk score 
was higher in group 3 than group 4. 
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obesity and ≤2 









obesity but with 





















Chinese 64.6 6.6 10.0 18.8 34.6   




8.5 10.4 36.2 22.4   
Female 
Chinese 77.7 6.7 3.4 12.1 22.1   




22.0 2.1 34.4 5.7   
1 group 3/group 3 + group 4 
2 p-value for comparing the distribution of individuals in all four groups by ethnic group estimated using chi-square analysis   Analyses were carried 
out separately for males and females. 
3 p-value for comparing the distribution  of individuals in group 3 and group 4 by ethnic group estimated using chi-square analysis   Analyses were 
carried out separately for males and females. 
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Table 8. Phenotypic characteristic (mean±SD) of various metabolic groups.  The 1998 Singapore National Health Survey.   
 
Group 1 
No central obesity 
and ≤2 risk factors 
n=3045 
Group 2 
Central Obesity with 0 
or 1 risk factor 
n=402 
Group 3 
No central obesity but 
with ≥3 risk factors 
n=316 
Group 4 
Central obesity with ≥ 
other 2 risk factors 
n=952 
p-value1 p-value2 
Age 35.1 ± 11.4 40.2 ± 10.8 44.7 ± 12.0 46.0 ± 11.6 <0.005 0.43 
Body mass index (kg/m2) 21.5 ± 2.7 27.7 ± 3.8 23.5 ± 2.2 28.5 ± 3.9 <0.005 <0.005 
Waist circumference (cm) 73.9 ± 7.6 90.2 ± 9.0 82.4 ± 5.8 93.6 ± 8.0 <0.005 <0.005 
Fasting glucose (mmol/L) 5.41 ± 0.99 5.54 ± 1.19 6.50 ± 2.20 6.92 ± 2.57 <0.005 <0.005 
SBP (mmHg) 116 ± 14 121 ± 13 134 ± 18 135 ± 19 <0.005 >0.99 
DBP (mmHg) 70 ± 10 75 ± 9 82 ± 11 83 ± 11 <0.005 >0.99 
Total cholesterol (mmol/L) 5.27 ± 1.00 5.59 ± 1.03 6.00 ± 1.14  6.03 ± 1.13 <0.005 >0.99 
Fasting triglyceride (mmol//L) 1.00 ± 1.55 1.17 ± 1.40 2.49 ± 1.54 2.32 ± 1.75 <0.005 <0.005 
HDL cholesterol (mmol/L) 1.48 ± 0.36 1.36 ± 0.30 1.05 ± 0.25 1.11 ± 0.28 <0.005 0.01 
LDL cholesterol (mmol/L) 3.24 ± 0.89 3.67 ± 0.92 4.03 ± 1.02  4.13 ± 1.04 <0.005 0.66 
Insulin resistance 1.26 ± 1.72 2.10 ± 1.72 2.10 ± 1.70 3.32 ± 1.93  <0.005 <0.005 
Framingham risk score 3.8 ± 4.9 4.3 ± 4.1 14.3 ± 10.7 12.8 ± 10.0 <0.005 0.002 
Diabetes mellitus, % 2.2 3.0 15.2 25.5 <0.005  
Exercise regularly, % 15.9 13.5 20.6 17.3 0.06  
Current smoking, % 13.4 10.7 27.8 16.6 <0.005  
Alcohol consumption, % 38.9 29.9 41.8 32.1 <0.005  
1 p-value for univariate ANOVA comparing all four groups 
2p-value for post-hoc test comparing group 3 and group 4 following Bonferroni correction for multiple testing 
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Table 9 shows the same phenotypic characteristics of individuals who met the criteria for the MS as 
recommended by the AHA/NHLBI and the IDF.  In this table, unlike table 8, the two groups are not 
mutually exclusive.  In fact, those who meet the criteria according to the IDF definition are a subset of 
those who meet the criteria according to the AHA/NHLBI definition.  The two sets of criteria identify 
individuals with very similar levels of cardiovascular risk factors. 
 
Table 9.  Comparison of cardiovascular disease risk factor levels between those with the metabolic 
syndrome identified by the American Health Association/National Heart Lung and Blood Institute 
(AHA/NHLBI) criteria and the International Diabetes Federation (IDF) criteria. 
Definition of the metabolic 
syndrome 
AHA/NHLBI N=1268 IDF N=952 
Age  45.7  (CI 22.3-69.1) 46.0 (CI 22.8-69.2) 
Body mass index (kg/m2)  27.3 (CI 18.9-35.7) 28.5 (CI 20.7-36.3) 
Waist circumference (cm)  90.8 (CI 72.8-108.8) 93.6 (CI 77.6-109.6) 
Fasting glucose (mmol/L)  6.81 (CI 1.01-12.61) 6.92 (CI 1.78-12.06) 
SBP (mmHg)  134 (CI 96-172) 135 (CI 97-173) 
DBP (mmHg)  83 (CI 61-105) 83 (CI 61-105) 
Total cholesterol (mmol/L)  6.02 (CI 3.76-8.29) 6.03 (CI 5.96-6.10) 
Fasting triglyceride (mmol//L)  2.43 (CI -1.25-6.11) 2.32 (CI 1.18-5.84) 
HDL cholesterol (mmol/L)  1.10 (CI 0.54-1.66) 1.11 (CI 0.55-1.67) 
LDL cholesterol (mmol/L)  4.11 (CI 2.04-6.17) 4.13 (CI 2.05-6.21) 
Insulin resistance  2.99 (CI -.087-6.85) 3.32 (CI -0.54-7.18) 
Diabetes mellitus, %  22.9 (CI 20.6-25.3) 25.5 (CI 22.9-28.4) 
Exercise regularly, %  18.1 (CI 16.1-20.3) 17.3 (CI 15.0-19.8)  
Current smoking, %  19.4 (CI 17.5-21.3) 16.6 (CI 14.4-19.1) 
Alcohol consumption, %  34.5 (CI 32.0-37.2) 32.1 (CI 29.3-35.2) 
Framingham risk score  13.1 (CI -7.3-33.5) 12.8 (CI -7.2-32.8) 




4.2.2  study 3:  Impact on associations with cardiovascular disease 
In this cohort study, there were 4,334 participants after excluding 92 participants with preexisting IHD and 
27 with missing data. These comprised 2,546 Chinese, 909 Malays, and 879 Asian Indians. There were 
2,087 male subjects and 2,247 female subjects. The mean duration of follow up was 9.6 ± 1.5 years and 
totaled 41,400 person-years. A total of 135 first IHD events were reported. Table 10 shows that the 
prevalence of the three central obesity/metabolic syndrome groups were: no metabolic syndrome, 73.8%; 
central obesity/metabolic syndrome, 17.7%; and no central obesity/ metabolic syndrome, 8.5%. Using the 
Asian criteria for waist circumference, the prevalence of metabolic syndrome according to the IDF was 
17.7% and 26.2% according to the AHA/NHLBI. The prevalence of the three groups was also different 
among the ethnic groups, with Asian Indians having the highest prevalence of metabolic syndrome in 
both the presence (28.6%) and absence (9.3%) of central obesity (Table 10).  
 
 Table 10 further describes the characteristics of the three central obesity/ metabolic syndrome groups. 
Compared with those with three or more metabolic syndrome components without central obesity, those 
with three or more components with central obesity were older, more obese, and had higher blood 
pressure. In addition, they were more likely to be female and of Malay or Asian-Indian ethnicity. However, 
in contrast, individuals with three or more metabolic syndrome components without central obesity had 
higher plasma triglyceride and higher fasting glucose values than those with three or more components 
with central obesity. Also, in this group, there was a higher proportion of current smokers (25.8%) 
compared with the group with three or more components with central obesity (15.6%) or no metabolic 





Table 10: Characteristics of study population by central obesity/metabolic syndrome groups.  CO=central 
obesity.  Met S=metabolic syndrome 
Characteristics No CO,  No Met S CO,  No Met S CO,  Met S No CO, Met S
N (row %) 2942 (67.9) 258 (6.0) 766 (17.7) 368 (8.5) 
 Gender1     
Males 1407 (47.8) 98 (38.0) 339 (44.3) 243 (66.0) 
Females 1535 (52.2) 160 (62.0) 427 (55.7) 125 (34.0) 
 Ethnic group 1      
Chinese 1911 (65.0) 106 (41.4) 309 (40.3) 220 (59.8) 
Malays 573 (19.5) 64 (24.8) 206 (26.9) 66 (17.9) 
Asian Indians  458 (15.6) 88 (34.1) 251 (32.8) 82 (22.3) 
Age (yrs) 2 36.4 (11.9) 41.9 (10.8) 48.8 (12.0) 47.9 (12.2) 
Total-Cholesterol (mmol/l) 2 5.2 (0.9) 5.5 (0.9) 5.9 (1.1) 5.8 (1.1) 
LDL-C (mmol/l) 2 3.4 (0.9) 3.8 (0.9) 3.9 (1.0) 3.8 (1.0) 
HDL-C(mmol/l) 2 1.3 (0.3) 1.1 (0.3) 1.0 (0.3) 0.9 (0.2) 
TG  0.9 1.2 1.9 2.2 
Fasting glucose (mmol/l) 2 5.3 (0.9) 5.4 (1.5) 6.5 (2.4) 6.8 (2.8) 
Systolic blood pressure (mmHg) 2 114.2 (15.2) 119.2 (14.2) 137.4 (21.9) 136.3 (20.3) 
Diastolic blood pressure (mmHg) 2 67.1 (10.8) 72.9 (9.7) 81.9 (11.9) 80.9 (11.5) 
Waist Circumference (cm) 2 71.1 (8.1) 89.6 (7.4) 92.6 (8.4) 79.8 (6.6) 
BMI (kg/m2) 2 21.6 (2.9) 28.3 (3.7) 29.0 (3.9) 23.8 (2.5) 
Diabetes Mellitus 1 41 (1.4) 5 (1.9) 120 (16.7) 59 (14.9) 
 Current Smoker1  549 (18.7)  31 (12.0)  119 (15.6)  95 (25.8) 
 Alcohol intake1  294 (10.0)  22 (8.5)  69 (9.0)  55 (14.9) 
 Study1     
NHS 92 2514 (85.5) 170 (65.9) 434 (56.7) 291 (79.1) 
NUHHS 428 (14.5) 88 (34.1) 332 (43.3) 77 (20.9) 
1 categorical variables: numbers and column percentages 






Table 11 shows the risk of IHD for the three central obesity/metabolic syndrome groups including and 
excluding individuals with type 2 diabetes. The highest incidence rates were for the central obesity/ 
metabolic syndrome and no central obesity/metabolic syndrome groups, which included diabetic patients 
at 8.8 and 9.5 per 1,000 person-years, respectively. Compared with the no metabolic syndrome group, 
individuals with central obesity/metabolic syndrome and no central obesity/metabolic syndrome had 
significantly increased risks for IHD with adjusted HRs of 2.8 (95% CI 1.8–4.2) and 2.5 (1.5– 4.0), 
respectively. A comparison of the central obesity/metabolic syndrome and no central obesity/ metabolic 
syndrome groups showed no significant difference in risk of IHD between them, with HR 1.0 (95% CI 0.6– 
1.5) and an absolute rate difference of 0.7 (95% CI:  -4.7 to 3.2) per 1,000 person-years).  
 
Table 11: Association of central obesity/metabolic syndrome groups with risk of ischemic heart disease 
(HR;  95%CI) 






per 1000 py 
HR (95%CI)* HR (95%CI) ** 
No CO, No Met S 39 (1.3) 28875.9 1.4 (0.9-1.8) 1.0 1.0 
CO, No Met S 5 (1.9) 2442.8 2.0 (0.7-4.8) 1.0 (0.4-2.6) 1.0 (0.4-2.6) 
CO, Met S 59 (7.7) 6715.9 8.8 (6.6-11.0) 2.6 (1.7-4.1) 2.7 (1.8-4.2) 
No CO, Met S 32 (8.7) 3365.9 9.5 (6.5-13.4) 2.7 (1.7-4.5) 2.8 (1.7-4.5) 
CO, Met S -vs-  
No CO, Met S  
   1.0 (0.6-1.5) 1.0 (0.6-1.5) 
 
* adjusted for age, gender, ethnic group and study 
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** adjusted age, study, ethnic group, gender, smoking (none/occasional/ex-smoker vs current), alcohol 
intake (none/occasional vs >=once/mth) 
Individuals with the metabolic syndrome using either the IDF or AHA/ NHLBI criteria were found to have an 
increased risk of IHD (Table 12). The exclusion of diabetic patients did not remarkably change the risk 
estimates for either the IDF or AHA/NHLBI criteria and adjusted HRs were similar (HR 2.3 [95% CI 1.5–3.6] 
using both criteria). The APE among those with metabolic syndrome according AHA/NHLBI criteria was higher 
(84%) than the IDF criteria (76%). Similarly, the APT was also found to be higher when the AHA/NHLBI 
criteria were used (57.6%) compared with the IDF criteria (36.4%). Although the APE did not change when 
diabetic patients were excluded from the analyses, the APT was lowered to 48.0 and 28.0% for the 
AHA/NHLBI and IDF criteria, respectively. 
 
Table 12—Risk of IHD (HR (95% CI) for individuals with the metabolic syndrome according to IDF and 
AHA criteria 
 N of events 
(%) 
Person-year Incidence rate (per 
1,000 person-
years) 
HR (95% CI) * HR (95% CI)† 
Including diabetic 
patients  
     
IDF criteria       
No MetS  76 (2.1)  34,685  2.1 (1.7–2.7)  1.0  1.0  
MetS  59 (7.7)  6,716  8.8 (6.6–11.0)  3.9 (2.8–5.5)  2.1 (1.4–3.1)  
AHA criteria       
No MetS  44 (1.4)  31,319  1.4 (0.9–1.8)  1.0  1.0  
MetS  91 (8.0)  10,082  9.0 (7.2–10.9)  6.3 (44–9.0)  2.7 (1.8–4.0)  
Excluding diabetic 
patients  
     
IDF criteria       
No MetS  58 (1.7)  32,994  1.8 (1.3–2.2)  1.0  1.0  
Met S 38 (6.7) 5, 013 7.6 (5.2-10.0) 4.2 (2.8-6.3) 2.3 (1.5-3.6 
AHA criteria      
No Met S 40 (1.3) 30,541 1.3 (0.9-1.7) 1.0 1.0 
MetS 56 (5.7) 7466 7.5 (5.5-9.5) 5.6 (3.7-8.4) 2.3 (1.5-3.6) 
*Unadjusted HRs. †Adjusted HRs for age, study, ethnic group, sex, LDL cholesterol, smoking (nonsmoker 
vs. current smoker), and alcohol intake (none/occasional vs. ≥1/month). MetS metabolic syndrome.
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4.3  Study 4: Disordered amino acid metabolism and it’s associations with insulin resistance. 
Table 13 presents demographic and clinical characteristics of the Chinese and Asian-Indian study 
participants, stratified by insulin resistance.  Individuals from the top tertile of insulin resistance in both ethnic 
groups had HOMA indices 3-4 times higher than those from the lowest tertile.   These differences were driven 
almost exclusively by elevations in fasting insulin levels in the high HOMA groups.   Despite our attempts to 
control for BMI, BMI was slightly higher in individuals with higher levels of IR.  Hip circumference was identical 
between the groups, whereas waist circumference, and consequently, waist-to-hip ratio, differred significantly 
between high and low HOMA subjects in both ethnic groups.   The HDL-C were significantly lower in both 
groups of Asian Indian subjects than in Chinese subjects, and HDL-C levels were lower in the high versus low 
HOMA subjects within both ethnic groups, whereas LDL-C levels were unaffected by HOMA tertile or ethnic 
origin.  TG levels were clearly elevated in the high HOMA subjects in both the Chinese and Asian Indian 
groups.  Finally, blood pressure (both systolic and diastolic) increased modestly in the high HOMA versus low 
HOMA subjects within both ethnic groups. 
 
Table 13.  demographic and clinical characteristics (mean±SD) of study subjects by insulin resistance and 
ethnic group. 














     
Age 46.82 ± 11.49 51.25 ± 11.35 50.84 ± 11.54 49.54 ± 7.05 0.037 
Height 169.42 ± 5.70 169.39 ± 6.85 172.80 ± 6.64 170.54 ± 7.54 0.067 
Weight 68.66 ± 7.34 70.48 ± 8.59 72.15 ± 7.57 72.73 ± 8.89 0.018 
BMI (body mass 
index) 23.89 ± 1.94 24.52 ± 2.13 24.16 ± 2.05 24.95 ± 2.10 0.017 
Waist 86.69 ± 6.32 90.60 ± 6.99 88.42 ± 12.41 93.18 ± 6.97 0.000006 
Hip 99.52 ± 5.27 99.98 ± 5.50 99.11 ± 12.67 101.50 ± 5.95 0.299 
WHR (waist-hip-
ratio) 0.87 ± 0.05 0.91 ± 0.05 0.89 ± 0.08 0.92 ± 0.05 0.000002 
SBP (systolic 


















blood pressure) 80.41 ± 9.80 84.63 ± 11.62 79.66 ± 10.14 82.56 ± 10.86 0.034 
Insulin (mU/L) 3.60 ± 1.07 12.98 ± 6.09 3.53 ± 1.22 14.76 ± 11.57 1.455e-28
Fasting glucose 
(mmol/L) 4.73 ± 0.50 5.29 ± 0.97 4.76 ± 0.57 5.83 ± 2.33 0.000002 
Cholesterol 5.17 ± 0.86 5.35 ± 0.82 5.09 ± 0.90 5.35 ± 0.83 0.292 
Triglyceride 1.30 ± 0.61 1.85 ± 0.96 1.38 ± 0.99 1.95 ± 1.22 0.000015 
Cholesterol: HDL 
ratio 4.24 ± 1.02 4.68 ± 1.22 4.98 ± 1.53 5.21 ± 1.13 0.000016 
HDL 1.33 ± 0.27 1.26 ± 0.24 1.15 ± 0.30 1.11 ± 0.20 0.000006 
LDL 3.25 ± 0.74 3.25 ± 0.74 3.29 ± 0.76 3.33 ± 0.87 0.924 
Fasting insulin 
(HOMA_IR) 0.75 ± 0.22 3.02 ± 1.58 0.74 ± 0.24 3.70 ± 3.02 1.222e-27
C-Reactive 
Protein (CRP) 3.63 ± 16.07 2.32 ± 3.34 1.85 ± 2.76 5.50 ± 17.39 0.4743 
      
Smoking      
Yes 35.1 42.0 36.7 38.0  
No 64.9 58.0 63.3 62.0 0.826 
Hypertension      
Yes 32.0 55.4 33.3 28.3  




     
Yes 13.2 25.8 12.0 7.0  
No 86.8 74.2 88.0 93.0 0.047 
 
Table 14 shows the dietary intake and physical activity in these individuals.  None of the subjects in this study 
were vegans.  As a proportion of total energy intake, Asian Indians consumed less protein and more 
saturated fat than Chinese.  However, no dietary differences were noted between high and low HOMA 
individuals in either ethnic group.  There was a trend towards less physical activity in individuals with high 
HOMA that was not statistically significant. 
86 
 













Dietary intake      
Total calories (kcal) 



















Total CHO (g) 









Total protein (g) 









Total saturated fat (g) 









Percent energy from fat 27.70 ± 4.95 27.43 ± 5.71 28.25 ± 6.41 29.56 ± 5.39 0.15
Percent energy from 
carbohydrate 57.50 ± 5.56 57.64 ± 6.89 57.27 ± 5.75 56.76 ± 5.72 0.868
Percent energy from 
protein 14.50 ± 1.65 14.65 ± 1.69 13.47 ± 2.07 12.92 ± 1.18 4.478e-09
Percent energy from 
SFA 10.82 ± 2.64 10.67 ± 2.24 11.49 ± 3.39 12.53 ± 3.05 0.001
Total weight of rice & 
alternatives (g) 



























      











Table 15 shows the metabolite concentrations in the various groups.  Free fatty acid levels did not differ 
between individuals with and without insulin resistance.  The most marked differences were observed 
amongst the amino acids.  Chinese subjects with high HOMA had higher levels of several amino acids than 
Chinese subjects with low HOMA.  These  included alanine, proline, valine, leucine/isoleucine, phenylalanine, 
tyrosine, glutamate/glutamic acid and ornithine.  With the exception of phenylalanine, all these differences 
remained statistically significant when adjusted for age and BMI.  Associations in the same direction were 
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observed in Asian Indians but reached statistical significance only for alanine, tyrosine and 
glutamate/glutamic acid.  We also measured a group of 20 urinary organic acids in all of the subject groups.  
Lactate and pyruvate levels were increased in urine in the high HOMA subjects of both ethnic groups; these 
changes were accompanied by highly significant increases in blood lactate levels as a function of HOMA, 
again in both ethnic groups.  Interestingly, isobutyrylglycine was significantly lower in the high HOMA vs low 
HOMA group in Asian Indians but not in Chinese, and isovalerylglycine showed a similar trend.  
Methylmalonate, methylsuccinate and hydroxymethylglutarate levels were all higher in urine of Asian Indian 
compared to Chinese subjects, but did not change significantly with HOMA in either ethnic group.  Finally, 
among 45 acylcarnitine species measured by MS/MS, C10:1 and C8:1-DC were low in insulin resistant 
individuals, but only in Asian Indians and not in Chinese.  C3 and C5 acylcarnitines, previously shown to be 
elevated in association with the increase in branched-chain amino acids in obese versus lean subjects from 
the Southeastern United States 58 trended higher in the high HOMA group in both the Asian Indian and 
Chinese men, but this change did not achieve statistical significance.   
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Table 15.  Metabolite concentrations by insulin resistance and ethnic group. Units of measure—acylcarnitines and amino acids, µM; urinary organic 
acids, mmol/mol creatinine. Abbreviations--AC, acylcarnitine; DC, dicarboxyl.  Analytes that showed statistically significant differences between any 1 


































(plasma) 323.530 315.751 0.2302 0.2078 0.283 335.762 320.775 0.1222 0.111 0.100 0.5383 
Ala 
(plasma) 388.547 424.497 0.0024 0.0023 0.0048 414.825 482.272 0.0006 0.0003 0.001 0.1487 
Ser 
(plasma) 132.873 135.764 0.4531 0.5270 0.4536 129.731 120.747 0.1903 0.2266 0.3553 0.1090 
Pro 
(plasma) 170.005 197.519 0.0002 0.0002 0.0007 196.922 204.526 0.4573 0.5057 0.6961 0.1234 
Val 
(plasma) 285.194 309.05 0.005 0.0023 0.0044 279.868 293.943 0.2985 0.3565 0.4232 0.5302 
Leu/lle 
(plasma) 202.756 216.067 0.0071 0.0110 0.0321 193.412 202.959 0.1545 0.1903 0.2131 0.6633 
Met 
(plasma) 31.186 31.830 0.4376 0.4145 0.4917 31.119 32.346 0.3257 0.3518 0.1724 0.698 
His 
(plasma) 77.644 75.100 0.0946 0.1298 0.0843 80.126 75.586 0.0535 0.0606 0.0732 0.4708 
Phe 
(plasma) 69.67 72.994 0.0202 0.0482 0.0879 67.701 71.542 0.0818 0.068 0.0555 0.8423 
Tyr 
(plasma) 69.006 77.855 1.3e-06 2.7e-06 2.3e-05 69.014 80.587 0.0002 0.0002 0.0002 0.4136 
Asx 
(plasma) 69.484 67.357 0.2545 0.3847 0.4303 66.071 68.197 0.3559 0.3194 0.4772 0.1857 




































(plasma) 103.063 118.721 0.0005 0.0009 0.0017 100.578 112.372 0.0747 0.0779 0.1157 0.6289 
Cit 
(plasma) 34.723 35.590 0.4822 0.6875 0.7016 37.376 36.412 0.6315 0.7592 0.6435 0.4255 
Arg 
(plasma) 79.464 80.861 0.6569 0.8501 0.6616 84.942 78.014 0.2034 0.2056 0.2774 0.1643 
Plasma Acylcarnitines 
C2 AC 
(plasma) 8.507 8.262 0.5331 0.2267 0.1923 8.486 8.635 0.7995 0.7468 0.6258 0.5800 
C3 AC 
(plasma) 0.549 0.555 0.8553 0.9586 0.9467 0.527 0.585 0.1975 0.1829 0.2350 0.3181 
C4/Ci4 AC 
(plasma) 0.261 0.286 0.1668 0.3529 0.2467 0.274 0.253 0.5488 0.6016 0.7340 0.2019 
C5:1 AC 
(plasma) 0.051 0.054 0.5427 0.8347 0.7399 0.050 0.051 0.8759 0.852 0.6257 0.7965 
C5's AC 
(plasma) 0.138 0.146 0.3412 0.3471 0.6472 0.144 0.154 0.4555 0.5609 0.6962 0.8458 
C4-OH AC 
(plasma) 0.042 0.042 0.8826 0.7846 0.6750 0.040 0.038 0.6273 0.7254 0.7278 0.6453 
C6 AC 











































(plasma) 0.154 0.164 0.5799 0.6664 0.9199 0.181 0.187 0.8169 0.6289 0.6370 0.9172 
C8 AC 
(plasma) 0.27 0.249 0.2218 0.2271 0.2195 0.253 0.216 0.3189 0.3311 0.5026 0.6639 
C5-DC AC 




(plasma) 0.03 0.029 0.5302 0.4178 0.398 0.041 0.037 0.2806 0.285 0.2154 0.5651 
C6-DC AC 
(plasma) 0.092 0.083 0.0698 0.0570 0.0558 0.085 0.09 0.5354 0.4697 0.3817 0.1292 
C10:3 AC 
(plasma) 0.065 0.064 0.8946 0.8134 0.6536 0.097 0.102 0.7453 0.6273 0.5653 0.7046 
C10:2 AC 
(plasma) 0.023 0.020 0.4707 0.4054 0.5181 0.019 0.035 0.0499 0.0521 0.0580 0.0328 
C10:1 AC 
(plasma) 0.219 0.199 0.0722 0.0704 0.1002 0.241 0.189 0.006 0.0077 0.0192 0.1363 
C10 AC 
(plasma) 0.430 0.390 0.1744 0.1982 0.1890 0.409 0.350 0.3006 0.3106 0.4489 0.7468 
C7-DC AC 
(plasma) 0.008 0.008 0.9802 0.6381 0.6420 0.006 0.014 0.0799 0.0970 0.1017 0.0786 
C8:1-DC 
AC 




(plasma) 0.077 0.068 0.0433 0.0370 0.0255 0.069 0.076 0.2978 0.2445 0.1474 0.0475 








































(plasma) 0.014 0.015 0.3903 0.7655 0.7375 0.014 0.016 0.1951 0.1625 0.1206 0.4378 
C14:2 AC 
(plasma) 0.060 0.055 0.2082 0.1906 0.3180 0.063 0.057 0.2484 0.2798 0.5638 0.7328 
C14:1 AC 
(plasma) 0.115 0.101 0.0529 0.0319 0.0373 0.112 0.108 0.7825 0.8094 0.9245 0.4432 
C14 AC 
(plasma) 0.045 0.044 0.8541 0.798 0.8634 0.052 0.057 0.2683 0.2386 0.1518 0.3009 
C14:1-
OH/C12:1-
DC AC  




(plasma) 0.014 0.016 0.0833 0.1532 0.1584 0.015 0.015 0.9540 0.9253 0.8149 0.3716 
C16:2 AC 
(plasma) 0.010 0.009 0.2994 0.1677 0.1580 0.011 0.010 0.1998 0.2541 0.3163 0.6676 
C16:1 AC 
(plasma) 0.027 0.025 0.1187 0.0257 0.0227 0.029 0.027 0.5191 0.5959 0.7885 0.8535 
C16 AC 









































(plasma) 0.00759 0.00736 0.6429 0.4812 0.4459 0.00928 0.00855 0.4824 0.5487 0.5074 0.6852 
C18:2 AC 
(plasma) 0.078 0.076 0.5949 0.401 0.4695 0.080 0.079 0.8162 0.9384 0.7658 0.9542 
C18:1 AC 
(plasma) 0.157 0.159 0.8048 0.8739 0.7325 0.144 0.158 0.1441 0.1036 0.0537 0.2411 
C18 AC 
(plasma) 0.062 0.064 0.3985 0.6536 0.6888 0.0612 0.0613 0.9815 0.9857 0.7807 0.6571 
C18:2-OH 
AC 








(plasma) 0.0101 0.0106 0.3725 0.6717 0.6111 0.0077 0.011 0.0013 0.0011 0.0002 0.0162 
C20:4 AC 
(plasma) 0.0130 0.0124 0.4483 0.5368 0.4253 0.0138 0.0134 0.7186 0.7608 0.8755 0.9005 
C20 AC 




(plasma) 0.009 0.010 0.1892 0.2868 0.2966 0.0105 0.0101 0.6800 0.7745 0.7896 0.2878 
C20-





































(plasma) 0.0069 0.0078 0.1179 0.1421 0.1743 0.0071 0.0079 0.2589 0.2662 0.3579 0.8842 
Conventional metabolites 
Lactate 
(plasma) 2.493 2.895 7.5e-06 3.5e-06 1.1e-05 2.244 3.022 2.4e-08 1.6e-08 5.7e-08 0.017 
Free fatty 
acids 
(plasma) 0.396 0.425 0.2354 0.3687 0.4965 0.381 0.423 0.2898 0.2566 0.2073 0.7687 
total 
ketones 
(plasma) 75.258 67.145 0.4832 0.2755 0.2726 59.133 51.660 0.5188 0.5306 0.7681 0.9733 
3-OH 
butyrate 
(plasma) 52.804 46.277 0.4505 0.2525 0.2683 40.867 35.585 0.5272 0.5466 0.8147 0.9302 
Urinary Organic Acids 
Lactate 
(urine) 7.294 9.07 0.0078 0.0233 0.02 6.904 8.795 0.0143 0.0099 0.013 0.9188 
Pyruvate 
(urine) 4.392 5.287 0.0013 0.0019 0.0037 4.362 5.988 0.0543 0.0572 0.0446 0.2927 
Methylmal
onate 
(urine) 1.037 0.945 0.361 0.1494 0.1437 1.562 1.528 0.9428 0.9828 0.9769 0.8690 
Ethylmalo
nate 
(urine) 4.040 4.178 0.5062 0.4475 0.4734 4.585 4.391 0.6375 0.6748 0.6582 0.4277 
Succinate 
(urine) 2.17 1.893 0.2673 0.1384 0.1941 1.802 1.746 0.8316 0.9249 0.7522 0.5984 





































(urine) 0.735 0.791 0.2147 0.2527 0.2445 0.766 0.814 0.6025 0.5077 0.4839 0.9285 
Isobutyrylg
lycine 
(urine) 0.527 0.511 0.5862 0.4722 0.7091 0.634 0.456 0.0141 0.0153 0.0084 0.0165 
Glutarate 
(urine) 0.506 0.690 0.1310 0.2468 0.1947 0.506 0.385 0.1150 0.1119 0.0785 0.1140 
Butyrylglyc
ine (urine) 0.608 0.643 0.4926 0.539 0.3933 0.631 0.617 0.8558 0.8876 0.8561 0.5991 
Isovalerylg
lycine 





(urine) 2.643 2.745 0.3128 0.3477 0.282 3.067 2.965 0.6893 0.7307 0.6532 0.3728 
Malate 
(urine) 1.443 1.574 0.5011 0.918 0.4734 1.368 1.812 0.1789 0.1613 0.6582 0.3948 
Adipate 
(urine) 0.824 1.024 0.0098 0.0159 0.0287 1.096 1.106 0.9424 0.9319 0.7929 0.2045 
-
Ketoglutar
ate (urine) 6.995 8.057 0.058 0.1302 0.1912 8.496 8.86 0.6866 0.6605 0.6122 0.5025 
Hexanoylg
lycine  
(urine) 0.264 0.261 0.8765 0.6605 0.6963 0.238 0.253 0.6288 0.6219 0.5635 0.6589 
Suberate 



































(urine) 0.654 0.591 0.1722 0.2615 0.2160 0.520 0.560 0.5201 0.4934 0.5718 0.2071 
Homovanil
late (urine) 2.045 1.982 0.4623 0.4728 0.4871 2.340 2.148 0.3376 0.3950 0.4545 0.4945 
Citrate 




Table 16 shows the hormonal and inflammatory profile of the various groups. In both ethnic groups, high 
HOMA was associated with elevated plasma leptin and reduced adiponectin, but in addition, leptin levels 
were clearly elevated in the Asian Indians compared to the Chinese regardless of HOMA group. IGF-1 levels 
were negatively associated with HOMA in Chinese, but this was no longer statistically significant after 
adjustment for age and BMI.  More strikingly, IGF-1 levels were higher in Chinese than in Indian subjects 
irrespective of the degree of IR.  IGFBP1 levels were sharply decreased as a function of HOMA in both ethnic 
groups, but overall levels were not different between Chinese and Asian Indian subjects.  Among cytokines, 
TNFα levels were elevated in high HOMA versus low HOMA tertiles, but these changes only reached 
statistical significance for Chinese subjects and were attenuated after adjustment for age and BMI.  
97 
 








































GM-CSF 9.109 2.648 0.2773 0.2767 0.3565 0.527 1.017 0.6109 0.5973 0.7298 0.4406 
IFN- 2.174 1.736 0.2697 0.262 0.3151 1.888 2.028 0.7549 0.7071 0.8696 0.3884 
IL-10 21.980 7.479 0.3180 0.3079 0.3969 3.903 6.625 0.6482 0.6308 0.7932 0.4402 
IL-12p70 29.336 11.284 0.2572 0.2609 0.3366 7.762 23.939 0.2271 0.2395 0.2448 0.1829 
IL-1 0.483 0.186 0.1328 0.1582 0.1437 0.459 0.244 0.2869 0.3368 0.2777 0.8019 
IL-2 4.351 3.864 0.7831 0.8086 0.9049 6.275 7.286 0.7985 0.8043 0.6251 0.6902 
IL-6 3.225 1.774 0.5495 0.3109 0.4088 1.285 1.460 0.4632 0.3469 0.3608 0.6578 
IL-8 3.594 3.021 0.4510 0.3163 0.2199 4.629 7.360 0.5316 0.5398 0.5574 0.2912 
TNF- 4.373 4.835 0.0336 0.1736 0.1515 4.881 5.342 0.4999 0.3988 0.3694 0.9964 
















































IGF1 204.228 185.466 0.0410 0.2625 0.5032 173.232 161.482 0.2467 0.1632 0.1339 0.6478 
IGFBP1 23581.284 17016.292 0.0066 0.0002 0.0013 24548.879 15555.552 0.0230 0.0319 0.0593 0.5867 
IGFBP2 1074002.9 909345.3 0.2711 0.0666 0.1282 1106115.4 695282.46 0.0127 0.0172 0.0270 0.3276 
IGFBP3 990534.53 894708.08 0.0506 0.0843 0.1371 857774.02 877290.3 0.7730 0.8308 0.9015 0.1842 
Adiponectin 7670.0674 6338.04 0.0074 0.0007 0.0056 8808.630 6334.192 0.0024 0.0043 0.0048 0.2123 
IGF1:IGFBP3 ratio 0.000247 0.000231 0.5284 0.5749 0.5567 0.000233 0.000202 0.2108 0.2208 0.3120 0.7040 
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4.4  Study 5: Genetic variants at the APOA1/C3/A4/A5 locus and their role in the pathogenesis of 
dyslipidemia. 
Table 17 shows the the characteristics of the study population.   
 






Age (Years) 37.6 ± 12.0 37.4 ± 11.9 
Triglyceride (mmol/L)a 1.39 (0.31-11.78) 1.01 (0.29-10.79) 
HDL cholesterol (mmol/L) 1.26 ± 0.31 1.56 ± 0.36 
LDL cholesterol (mmol/L) 3.53 ± 0.94 3.23 ± 0.92 
Total cholesterol (mmol/L) 5.50 ± 1.03 5.31 ± 1.03 
Waist Circumference (cm) 83.8 ± 9.77 72.9 ± 8.40 
BMI (kg/m2) 23.4 ± 3.68 22.0 ± 3.56 
Waist-to-hip ratio 0.87 ± 0.06 0.78 ± 0.05 
Fasting glucose (mmol/L) 5.64 ± 0.86 5.42 ± 1.04 
Systolic blood pressure (mmHg) 124.8 ± 14.6 116.6 ± 16.0 
Diastolic blood pressure (mmHg) 77.3 ± 10.6 70.4 ± 10.7 
Data are means ± SD, unless otherwise stated. 
a Geometic mean and range shown as distribution was skewed. 
 
Table 18 shows the allele frequencies of the polymorphisms studied along with an assessment of 
deviation from Hardy-Weinberg Equilibrium.  A total of 62 SNPs were genotyped.  28 SNPs with mean 
allele frequency < 0.01 (23 in total) or extreme deviations from Hardy Weinberg Equilibrium (5 in total) 
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were not included in any further analyses.  This left a total of 34 SNPs that were included for association 
testing. 
  
Table 18.  Single Nucleotide polymorphisms genotyped in this study.  SNPs highlighted in grey were not 
considered in subsequent analyses. 
 Rs# HWE p-value MAF 
Apolipoprotein A5 
1 rs2266788 (1259T>C) 0.001 0.184 
2 rs2075291 0.737 0.059 
3 rs2072560 (+476G>A) 0.001 0.184 
4 rs3135506 (56C>G) 0.0319 0.193 
5 rs651821 (-3A>G) 1 0.001 
6 rs662799 (-1131T>C) 0.102 27.6 
Apolipoprotein A4 
8 rs675 (Thr347Ser) 1 0.0003
9 rs5109 0.1315 0.005 
10 rs5108 1 0.001 
11 rs5107 1 0.001 
12 rs5106 1 0.0005
13 rs2238008 0.0099 0.001 
14 rs5105 1 0.0002
15 rs12721043 1 0.001 
16 rs2234668 0.0661 0.004 
17 rs5104 (Hinc II) 0.8107 0.308 
18 rs6413456 0.6866 0.034 
19 rs6413455 1 0 
20 rs5101 1 0.001 
21 rs5100 0.8899 0.365 
22 rs5099 9x10-4 0.004 
23 rs5098 1x10-5 0.007 
24 rs5096 0.6941 0.374 
25 rs5095 3x10-4 0.003 
26 rs5094 0.5183 0.058 
27 rs2239013 0.367 0.039 
28 rs5093 0.0791 0.213 
29 rs5092 0.2343 0.372 
30 rs12721041 0.081 0.004 
31 rs5091 0.0011 0.001 
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32 rs5090 1 0.002 
33 rs5089 1x10-20 0.012 
Apolipoprotein C3 
34 rs33989105 (-482) 0.4852 0.421 
35 rs35523410 (-455) 0.2572 0.434 
36 rs618354 1 0.0002
37 rs2070669 3x10-04 0.443 
38 rs2070668 0.6497 0.45 
39 rs4520 (1100 C>T) 0.5693 0.409 
40 rs5134 7x10-33 0.145 
Rs# HWE p-value MAF 
41 rs5132 0.6985 0.081 
42 rs5130 0.1635 0.425 
43 rs5128 (Sst I) 1 0.286 
44 rs4225 1.2x10-31 0.256 
Apolipoprotein A1 
45 rs12721025 0.6986 0.037 
46 rs5081 0.5369 0.079 
47 rs5080 1 0 
48 rs5079 1 0 
49 rs5077 1 0 
50 rs5076 1x10-5 0.05 
51 rs5075 1 0 
52 rs17243102 0.2913 0.332 
53 rs17243109 0.8244 0.039 
54 rs5073 1x10-20 0.012 
55 rs5072 0.2745 0.29 
56 rs2070665 0.141 0.292 
57 rs17249477 0.6337 0.036 
58 rs5070 (317 C>T) 0.4283 0.285 
59 rs670 (-75 G>A) 0.0043 0.271 
60 rs17243123 0.0234 0.042 
61 rs12718467 0 0.423 





None of the SNPs showed a statstically significant association with either total cholesterol or LDL-
cholesterol.  However, multiple SNPs across all 4 loci showed statistically significant associations with  
both triglyceride and HDL-cholesterol (tables 19 and 20).  The strongest associations for both TG an 
HDL-C were at the APOA5 locus.  Since 4 of the 5 SNPs that showed a statistically significant association 
with TG are know to be in strong linkage disequilibrium in both our population and in populations of 
European ancestry.  These are rs2266788, rs2072560, rs651821 and rs662799 and the rare alleles for 
these polymorphisms are present on haplotype*2 described in the previous studies79, 119-121.  In addition, 
rs2075291 which had been identified in association with TG in Chinese subjects in the US 82 and in 
Taiwan also showed a strong association with both TG and HDL.  
 
 Figure 6 shows the pattern of linkage disequilibrium for the SNPs that showed the strongest associations 
with TG.   It can be seen that that the polymorphisms that show a statistically significant association with 
triglyceride represent 3  blocks of relatively high LD, corresponding to the APOA5, APOA4 and 
APOA1/C3 loci.  In the apoA5 block, it was also noted that rs2075291 showed a strong association with 
TG, but the degree of LD between other SNPs within that block was relatively low.  In particular, the R2 
between this SNP and rs662799, the SNP that shows the strongest association with TG and HDL-C in 
this study, was only 0.14.  To test the hypothesis that multiple variants at these loci contribute to the 
variation of TG and HDL in this population, we carried out additional analyses adjusting for rs662799 (the 
top hit from the haplotype previously associated with TG) as well as rs2075291.  We found that 
adjustment for rs662799 attenuated the association between all other SNPs and TG such that none of the 
SNPs showed a statistically significant association with TG, except for rs662799. Adjustment for 
rs2075291 also attenuated the associations between other SNPs and TG, although may remained 
statistically significant.  Interestingly, adjustment for rs2075192 significantly attenuated the association 
between rs662799 and TG (the p-value increased from 9.6 x 10-19 in the unadjusted analysis to 7.1 x 10-
11 in the adjusted analysis).   
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Table 19.  Associations between SNPs at the APOA1/C3/A4/A5 locus and triglycride amongst Chinese in 
NHS98.  The numbering of the SNPs is kept in line with table 18 even though SNPs with allele 
frequencies <0.01 have been removed from the table. 
Apolipoprotein A5 BETA* Unadjusted Adjusted for rs2075291 Adjusted for rs662799 
1 rs2266788 
(1259T C)
0.11 1.3x10-7 4.9x10-9 0.998 
2 rs2075291 0.20 3.2x10-11 NA 7.1x10-11 
3 rs2072560 
( 476G A)
0.10 5.7x10-9 6.7x10-11 0.007 
4 rs3135506 (56C>G) -0.26 0.248 0.183 0.211 
6 rs662799 (-1131T>C) 0.14 9.6x10-19 7.1x10-11 NA 
Apolipoprotein A4 
17 rs5104 (Hinc II) 0.09 5.6x10-8 2.2x10-6 0.005 
18 rs6413456 -0.08 0.493 0.676 0.869 
21 rs5100 0.06 3.2x10-5 1.9x10-4 0.171 
24 rs5096 0.06 3.3x10-5 2.8x10-4 0.145 
26 rs5094 -0.01 0.701 0.902 0.701 
27 rs2239013 -0.02 0.589 0.619 0.932 
28 rs5093 -0.03 0.143 0.037 0.696 
29 rs5092 0.07 1.7x10-6 2.2x10-5 0.044 
Apolipoprotein C3 
34 rs33989105 (-482) -0.01 0.388 0.529 0.607 
35 rs35523410 (-455) 0.01 0.534 0.617 0.551 
37 rs2070669 -0.04 0.017 0.002 0.32 
38 rs2070668 -0.03 0.045 0.001 0.977 
39 rs4520 (1100 C>T) -0.05 0.003 0.003 0.454 
41 rs5132 -0.05 0.08 0.21 0.433 
42 rs5130 0.04 0.018 0.002 0.394 
43 rs5128 (Sst I) 0.07 8x10-6 1.3x10-6 0.033 
Apolipoprotein A1 
45 rs12721025 -0.02 0.693 0.956 0.879 
46 rs5081 -0.05 0.067 0.187 0.457 
50 rs5076 -0.09 0.01 0.037 0.021 
52 rs17243102 0.05 0.001 0.001 0.417 
53 rs17243109 0.00 0.959 0.756 0.66 
55 rs5072 0.07 2.4x10-5 9.5x10-6 0.077 
56 rs2070665 0.06 2.1x10-4 6.7x10-5 0.117 
57 rs17249477 -0.06 0.15 0.303 0.532 
58 rs5070 (317 C>T) -0.04 0.009 0.009 0.433 
59 rs670 (-75 G>A) -0.01 0.609 0.326 0.581 
60 rs17243123 -0.11 0.003 0.01 0.006 





Figure 6.  Pattern of linkage disequilibrium for the SNPs at the APOA1/C3/A4/A5 locus that show the 
strongest associations with TG in the Chinese population in NHS98. 
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The associations with  HDL-C were a little different (table 20 and figure 7).  As with TG, the strongest 
associations for HDL-C were with SNPs at the APOA5 locus.  However, SNPs that showed an 
association with HDL-C were generally found to involve only 2 haplotype blocks (in the APOA5 and 
APOA1 loci) with effectively no evidence of linkage disequilibrium between them.  Adjustment for 2 SNPs 
at the APOA5 locus has little impact on the association between SNPs in APOA1 and HDL-C.  
  
Figure 7.  Pattern of linkage disequilibrium for the SNPs at the APOA1/C3/A4/A5 locus that show the 
strongest associations with HDL-C in the Chinese population in NHS98. 
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Table 20.  Associations between SNPs at the APOA1/C3/A4/A5 locus and triglycride amongst Chinese in 
NHS98.  The numbering of the SNPs is kept in line with table 18 even though invariant SNPs have been 
removed from the table. 
Apolipoprotein A5 BETA Unadjusted Adjusted for rs2075291 Adjusted for rs662799 
1 rs2266788 -0.05 3.3x10-4 5.2x10-5 0.831 
2 rs2075291 -0.14 8.2x10-11 NA 1.9x10-6 
3 rs2072560 -0.03 0.009 0.001 0.002 
4 rs3135506 (56C>G) 0.12 0.447 0.34 0.406 
6 rs662799 (-1131T>C) -0.06 2.4x10-8 0.005 NA 
Apolipoprotein A4 
7 rs9282601 -0.04 0.019 0.024 0.009 
17 rs5104 (Hinc II) -0.04 0.001 0.003 0.189 
18 rs6413456 0.05 0.536 0.776 0.549 
21 rs5100 -0.02 0.124 0.178 0.608 
24 rs5096 -0.01 0.16 0.271 0.589 
25 rs5095 -0.10 0.258 0.259 0.441 
26 rs5094 0.02 0.286 0.47 0.682 
27 rs2239013 -0.02 0.351 0.434 0.234 
28 rs5093 0.01 0.502 0.098 0.942 
29 rs5092 -0.02 0.103 0.191 0.767 
Apolipoprotein C3 
34 rs33989105 (-482) 0.00 0.863 0.853 0.191 
35 rs35523410 (-455) 0.01 0.314 0.279 0.044 
37 rs2070669 0.01 0.605 0.231 0.593 
38 rs2070668 0.00 0.769 0.153 0.264 
39 rs4520 (1100 C>T) 0.01 0.294 0.363 0.747 
41 rs5132 0.03 0.066 0.152 0.204 
42 rs5130 0.00 0.749 0.72 0.164 
43 rs5128 (Sst I) -0.03 0.021 0.01 0.427 
Apolipoprotein A1 
45 rs12721025 -0.03 0.325 0.245 0.287 
46 rs5081 0.04 0.046 0.143 0.204 
50 rs5076 0.08 0.001 0.002 0.001 
52 rs17243102 -0.01 0.396 0.27 0.424 
53 rs17243109 -0.02 0.404 0.296 0.312 
55 rs5072 -0.02 0.043 0.018 0.749 
56 rs2070665 -0.02 0.096 0.055 0.993 
57 rs17249477 0.02 0.442 0.683 0.752 
58 rs5070 (317 C>T) 0.01 0.36 0.488 0.737 
59 rs670 (-75 G>A) 0.00 0.987 0.609 0.965 
60 rs17243123 0.10 1.6x10-4 0.001 1.8x10-4 




We also tested the hypothesis that these SNPs identified might modulate the association between obesity 
and TG or HDL-C.  We only examined interactions for SNPs that showed the greatest independent 
effects on the traits of interest.  For TG, we examined interactions between waist circumference and 
rs662799 and rs2075291 at the APOA5 locus.  For HDL-C, we also examined  rs17243123 at the APOA1 
locus.  The interaction term for rs662799 and waist circumference was statistically significant (p=0.002).  
The nature of the interaction is depicted in figure 8.  The presence of the rare allele was associated with a 
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Figure 8.  Interaction between rs662799 and waist circumference in relation to serum triglycerides.  The 




Chapter 5 DISCUSSION 
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5.1  Major findings and implications 
 
5.1.1  Study 1 
Several things are evident from our first study.  First, the metabolic syndrome is common.  In studies that 
included those with diabetes mellitus, the prevalence was 20-30% of Caucasian populations 123-126.  When 
individuals with diabetes mellitus were excluded, the prevalence was 10-15% 127, 128.  Second, in several 
populations, the presence of the MS identifies persons at increased risk of cardiovascular disease (CVD), 
CVD mortality or total mortality.  This has been demonstrated in both cross sectional studies 125, 129-131 and 
prospective studies 124, 127, 128, 132-135.  Finally, measures taken to reduce CVD risk are as effective in this 
sub-population of individuals as in those without the MS 135, 136.  For these reasons, it has been suggested 
that the diagnosis of MS is an effective means to target individuals for more intensive measures to reduce 
the morbidity and mortality attributable to CVD.   
 
As in Caucasian populations, the metabolic syndrome is also common in Asian populations.  Amongst 
non-diabetic individuals, the prevalence was 12.5% in Korea137 according to NCEP ATP III criteria.  In this 
study, prior to the exclusion of those with diabetes mellitus and pre-existing IHD, the prevalence was 
12.9%.  Dyslipidemia is particularly common in our population with 46.9% of men and 51.3% of women 
exhibiting low HDL-C concentration.  This is in line with our previous findings showing that insulin 
resistance and low HDL-C concentration are common findings in our population, particularly amongst 
those of Malay and Asian Indian ethnic groups 93.  However, to our knowledge, there is no data linking the 
MS to CVD in these populations.  Our study demonstrates, for the first time, that the metabolic syndrome 
is associated with a three-fold increased risk of IHD events in Singapore.  This increased risk remained 
statistically significant even after adjustment for age, sex and current cigarette smoking.  These findings 
are in line with the findings of previous studies in Caucasian populations 124, 127, 128, 132-135 but in contrast to 
those in American Indians who participated in the Strong Heart Study 138.  This highlights the importance 
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of the metabolic syndrome in Asian populations, which are likely to be most affected by the rising burden 
of CVD in the next several decades 4.  Furthermore, the effect of the metabolic syndrome on the risk of 
IHD did not appear to be modified by gender or ethnic group.  Although the metabolic syndrome has been 
associated with increased risk of CVD in women 123, 125, 126, at least 1 study has suggested that the effect 
may be modified by gender 131. 
 
One other aspect of our study is important.  Data from Singapore had previously demonstrated that for 
any given percentage of body fat, the body mass index (BMI) of Singaporeans were 3 kg/m2 lower than 
that in Caucasians 139.  A review of other Asian data also concluded that Asians had a higher percentage 
body fat at a lower BMI compared with Caucasians23. Subjects of Chinese descent have been shown to 
have similar risk of developing glucose intolerance at lower BMI compared with indigenous Europeans 140, 
141. A study conducted in Asian Indians suggested that these findings involving BMI also apply to other 
anthropometric indices such as the WC 142.  We have previously shown, in a cross sectional analysis of 
the Singapore population, that a WC of 80 cm in women and 90 cm in men best predicted the presence of 
at least two other features of the MS31 and suggested that these may be more appropriate as cut-offs to 
identify those with the MS in an Asian Population. 
 
This modification of the diagnostic criteria resulted in an increase in the prevalence of the MS to levels 
similar to those in the United States population.  However, the ultimate test of clinical utility for these 
modified Asian criteria for the metabolic syndrome lies in their ability to identify persons at risk of CVD.  
Our study shows that the suggestion to modify the NCEP ATP III criteria by reducing the level of WC used 
to define central obesity is appropriate, in relation to predicting the risk of IHD.  The lower WC, in 




The magnitude of the risk associated with this definition of the metabolic syndrome in our population 
(OR2.13;  95% CI 0.99-4.58) was similar or greater than that when the NCEP ATPIII criteria were used in 
Western populations.  In a review by Earl S. Ford in 2005143, a meta-analysis of 8 studies that used the 
NCEP ATP III definition of the metabolic syndrome showed an odds ratio of 1.65;  95% CI1.38-1.99) for 
cardiovascular disease. 
 
Furthermore, modification of the diagnostic criteria increased the sensitivity of the metabolic syndrome for 
identifying those at risk of IHD with little loss in specificity and increased the population attributable risk 
associated with the metabolic syndrome. 
 
Our study confirms our belief that the metabolic syndrome is a predictor of IHD in Asians without diabetes 
mellitus.  However, if the NCEP ATP III criteria are to be used in this population, there is a need to lower 
the cut-off for waist circumference to improve the identification of those at risk of CVD.  There remain 
many unanswered questions.  It has been suggested the metabolic syndrome identifies a subgroup of 
subjects amongst those with diabetes mellitus which are at particularly high risk of cardiovascular disease 
131.   Our study was not adequately powered to make this assessment (data not shown).  Furthermore, we 
were unable to assess the potential role of adding other features of the metabolic syndrome to the 
diagnostic criteria.  Potentially, these could include albuminuria, as proposed by the WHO 144 or C-




5.1.2  Study 2. 
Our data suggests that central obesity is important for the identification of individuals with insulin 
resistance and glucose intolerance.  Those individuals who had central obesity and at least 2 other 
features of the metabolic syndrome (in line with the IDF recommendations) were the most insulin resistant 
and the most likely to have diabetes mellitus.  Even amongst those with central obesity but with less than 
1 other risk factor, significantly elevated insulin resistance was observed in comparison to the normal 
population.   
 
However, central obesity does not appear to be a pre-requisite for the presence of the other 
cardiovascular risk factors associated with the metabolic syndrome.  In fact, a significant proportion of 
individuals in our population (ranging from 10-13% in men and 2-4% in women) exhibited multiple 
features of the metabolic syndrome even in the absence of central obesity.  These individuals would be 
diagnosed as having the metabolic syndrome according to the AHA/NHLBI criteria and not by the IDF 
criteria.  These individuals have elevated blood pressure and LDL-C which are comparable to levels 
observed in those who meet the IDF definition of the MS.  In addition, they have higher fasting TG and 
lower HDL-C, both of which are independent risk factors for cardiovascular disease 60, 145.  The findings of 
higher TG and lower HDL-C in this group of individuals are a consequence of the definition applied.  
Since these individuals are not centrally obese, qualification for the diagnosis of metabolic syndrome with 
three or more risk factors means that the other risk factors, including hypertriglyceridemia or low HDL-C, 
would need to be more common.   
 
The originally stated rationale for the criteria is that the syndrome components are associated with insulin 
resistance. This seems like a valid reason for attempting to diagnose the metabolic syndrome since 
insulin resistance has been shown to be a predictor of both diabetes mellitus and cardiovascular disease 
146-149.  Precise assessment of insulin resistance is technically difficult.  Less precise estimates of insulin 
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resistance, using fasting insulin as a surrogate measure, are also difficult to use clinically in the absence 
of well-standardized assays for plasma insulin. Thus a robust, biologically valid construct for the 
identification of insulin resistant individuals is desirable for use in clinical practice.  In this regard, our 
study suggests that the IDF recommendation might be more appropriate since it identifies a segment of 
the metabolic syndrome population that is more insulin resistant.  This may be particular relevant for the 
identification of those at increased risk of diabetes mellitus, given previous findings that, amongst features 
of the metabolic syndrome, it is the factors associated with insulin resistance that best predict diabetes 
mellitus 150. The greater degree of glucose intolerance identified using the IDF criteria would seem to 
support this conclusion.   
 
In contrast, if the purpose of defining the metabolic syndrome is to identify individuals at increased risk of 
cardiovascular disease, it is possible that the IDF definition misses a significant proportion of the 
population at increased risk.  The IDF definition of the metabolic syndrome identifies only a subset of 
those identified by the AHA/NHLBI definition.  The latter includes additional individuals who exhibit high 
levels of several other cardiovascular disease risk factors including greater age, higher LDL-C, higher 
serum triglyceride, lower HDL-C and higher blood pressure.  Each of these is an independent risk factor 
for cardiovascular disease.  The higher Framingham risk score of individuals in this group would seem to 
support this hypothesis.  Given these findings, the AHA/NHLBI definition may be more effective in 
identifying those at increased risk of cardiovascular disease.    
 
Our data also suggests that other factors may influence the phenotype associated with central obesity or 
insulin resistance.  Examples include age, cigarette smoking and alcohol intake, all of which are 
significantly associated with the presence or absence of other features of the MS in the face of central 
obesity. Although our study highlights the importance of the role  that lifestyle factors may play in the 
pathogenesis of the metabolic syndrome, this association between llifestyle factors and alcohol are not 
novel.   It has been shown in several previous studies that smoking and alcohol consumption have an 
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adverse effect on the risk of the metabolic syndrome and it’s associated features.  151-158.  Specifically, in 
relation to the lipid related features of the MS, cigarette smoking is known to cause low HDL-C  (one of 
the features of the MS) through its effects on lipid and lipoprotein metabolism (reviewed in Chellend 
Campbell et al159) while alcohol ingestion, particularly in excess, causes hypertriglyceridemia160-163. 
 
In conclusion, our study suggests that harmonization of the diagnostic criteria alone does not solve the 
problems associated with defining the metabolic syndrome. The AHA/NHLBI and the IDF definitions for 
MS identify different segments of the population. Importantly, there is a subset of individuals who meet 
the AHA/NHLBI recommendation for MS but will be missed if IDF recommendation is used. Although 
these individuals exhibit no central obesity, they have similar risk factors for cardiovascular disease and 
may benefit from similar risk reduction therapy.   
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5.1.3  Study 3 
Our study showed that the prevalence of the metabolic syndrome is 17.7% based on IDF criteria but 
26.2% based on AHA/NHLBI criteria. This meant that 8.5% of the population had three or more metabolic 
syndrome components in the absence of central obesity while using the Asian definition. Thus, making 
central obesity an “essential” rather than “optional” component in diagnosing metabolic syndrome fails to 
identify a fairly large proportion of individuals who otherwise would be classed as having the metabolic 
syndrome.  
 
Our study also showed that individuals with central obesity/metabolic syndrome and no central 
obesity/metabolic syndrome groups are at similar risk of IHD. This suggests that including central obesity 
as an “essential” component for the diagnosis of metabolic syndrome, as proposed by IDF, does not add 
more to the identification of individuals at increased risk of IHD. These findings from our study suggest, at 
least in this Asian population that having central obesity as an “optional” component of the metabolic 
syndrome instead of an “essential” component identifies a significantly greater number of individuals at 
increased risk of IHD. From the absolute measures, the APE and APT using the AHA/NHLBI criteria was 
higher than the IDF criteria. Thus, individuals with the metabolic syndrome, using the AHA/NHLBI criteria, 
can attribute a higher proportion of their risk of IHD to the metabolic syndrome. Similarly, a higher 
proportion of the risk of IHD for the total study population can be attributed to metabolic syndrome using 
the AHA/NHLBI rather than the IDF criteria.  
 
The IDF based their recommendation on the strength of the evidence linking waist circumference with 
CVD and the other components of the metabolic syndrome 164, 165 and states that central obesity is an 
early step in the etiological cascade leading to the full metabolic syndrome. Our findings refute neither of 
these premises. Indeed, one study 166 in Japan has shown that visceral adiposity was a crucial 
determinant on the degree of insulin resistance associated with the presence of other metabolic 
syndrome components. In that study, the presence of three or more metabolic syndrome components 
was associated with a lesser degree of insulin resistance if visceral adiposity was not one of the three 
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components (versus if it was). However, in relation to identifying individuals at increased risk of IHD, it 
does appear that central obesity adds to the risk of IHD in much the same way as the other four risk 
factors. This is in line with the findings of Katzmarzyk et al167 who showed that increasing waist 
circumference was associated with increased risk of CVD mortality when added to the other components 
of the metabolic syndrome. However, the presence of central obesity as one of the components of 
metabolic syndrome does not appear to alter the association between the presence of other multiple 
components and the risk of IHD. Thus, while making central obesity an essential requirement may make 
etiological sense and may be relevant to the identification of the insulin-resistant individual, the evidence 
that this approach is important for the identification of individuals at risk of IHD is limited at this time.  
 
Several factors could also explain our findings. First, central obesity may not cause IHD directly but rather 
through the associated risk factors and thus may not have a strong influence on the risk of IHD in this 
study until after the other CVD (metabolic syndrome) risk factors associated with central obesity have 
developed. Second, waist circumference is an imperfect surrogate of abdominal adiposity 168, and using it 
might lead to misclassification of individuals. Finally, central obesity is important, but the threshold for 
Asians may need to be further lowered. The underlying purpose for diagnosis of the metabolic syndrome 
is to identify individuals who are at increased risk of developing diabetes and CVD and to apply 
preventive measures 21, 22. We found in Asians that both individuals with and without central obesity and 
other metabolic syndrome components are at similar risk of IHD. The current AHA/NHLBI 21 proposal 
includes all of these individuals, while a sizable number who do not have central obesity but have the 
metabolic syndrome are omitted by the IDF 22 criteria and thus identifies a greater proportion of those at 
increased risk of IHD. However, we cannot comment at this time on the relevance of central obesity as an 
essential component of the metabolic syndrome in relation to the risk of diabetes due to lack of follow-up 
data. It may well be that the impact differs from that for IHD. Finally, of note is the high proportion of 
current smokers in the group of individuals without central obesity but with the metabolic syndrome 
compared with the other two groups. Although this has been adjusted for in the analysis to determine the 
risk of IHD for each group, it is still important to remember that the focus on the metabolic syndrome 
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should not lead to negligence of the other CVD risk factors that need to be addressed at the individual 
level.  
 
In conclusion, this study has shown that the risk of IHD is increased in individuals with the metabolic 
syndrome with or without central obesity. However, the prevalence of metabolic syndrome is increased by 
8.5% if central obesity is “optional” rather than “essential” and thus identifies more individuals at risk of 
IHD. Apart from metabolic syndrome, other CVD risk factors in individuals should also be considered and 




5.1.4 Study 4 
In this study, by using a comprehensive metabolic profiling approach, we have found a striking association 
between a subset of amino acids and insulin resistance in Chinese subjects living in Singapore.  In a previous 
study that applied the same tools to a group of obese (BMI 37 kg/m2) versus lean (BMI 23 kg/m2) African-
American and Caucasian subjects residing in the Southeastern United States, striking increases in amino acid 
levels were also noted in the obese and insulin resistant subjects, including branched chain amino acids 
(BCAA) and several of their metabolites 58.   The current findings strongly support the idea that these changes 
are related to IR rather than obesity per se, since we observed the changes in high versus low tertiles of IR in 
a group of Chinese subjects with a mean BMI of approximately 24 kg/m2.   
 
 
We recognize that this conclusions is based on the fact that insulin resistant and insulin sensitive subjects in 
this study were matched for BMI.  BMI is an imperfect measure of adiposity and therefore, there remains the 
possibility that the associations between plasma amino acids and insulin resistance are a consequence of 
residual confounding by adiposity, despite our attempts to correct for this by matching, and subsequently 
adjusting for BMI.  Nevertheless, our conclusions are supported by the finding that  rats fed a high fat diet 
supplemented with BCAA had reduced food intake and lower body weight relative to rats fed unsupplemented 
high fat diet, but had the same degree of insulin resistance 58.   
 
Unfortunately, the number of Asian Indian subjects available limited the power of this study to detect 
associations with insulin resistance in this ethnic group.  For this reason, several of the associations observed 
in Chinese were not statistically significant in Asian Indians.  Nevertheless, the effects of insulin resistance on 
BCAA and related amino acids trended in the same direction as observed in Chinese.  Furthermore, the 
effects on downstream catabolic products (alanine, glutamine/glutamate, lactate and pyruvate) were 
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sufficiently large to reach statistical significance.  As such, we believe that the observations in Chinese are 
also applicable to Asian Indians (although this needs to be confirmed in larger study).   
 
BCAA are major donors of amino groups for the synthesis of the gluconeogenic amino acids alanine and 
glutamate, and their levels are also closely correlated with tyrosine and phenylalanine in this and several 
other recent studies 58, 116, 169.  In situations of impaired BCAA oxidation (such as maple syrup urine disease), 
serum levels of alanine are reduced 170.  In contrast, the current study documents increases in the levels of 
pyruvate, lactate, alanine, and glutamate/glutamine in insulin resistant individuals, consistent with a model of 
increased supply and catabolism of BCAA in insulin resistant subjects. 
 
What is the source of the increased supply of BCAAs in insulin resistant subjects? As essential amino acids, 
BCAA levels in blood are controlled by dietary intake, their rate of utilization for the anabolic processes of 
protein biosynthesis and cell growth, their rate of catabolism through transamination and the branched-chain 
keto acid dehydrogenase complex, and the rate of protein turnover/hydrolysis.  In a prior study, it was 
reported that obese individuals consumed more protein than lean individuals (a difference that was of 
borderline statistical significance) 58.  However, in the present study, whereas dietary protein intake differed 
between ethnic groups, it did not differ between individuals with high or low HOMA.  We suggest that the 
increased supply of BCAA in individuals with high HOMA instead results from increased protein catabolism.  
In support of this idea, Gougeon et al compared a number of measures related to protein metabolism in three 
groups of individuals who were lean, obese without diabetes and obese with diabetes 171.  As in our prior 
study 58 obesity was associated with increased protein intake.  However, this difference disappeared after 
correcting for fat-free mass.  When they compared obese individuals with and without type 2 diabetes 
mellitus, no difference in protein intake was observed, but net negative nitrogen balance was observed in 





Despite similar BMI, insulin resistant and insulin sensitive individuals in the current study had markedly 
different waist circumferences. The differences observed in waist circumference suggest that despite similar 
BMI, individuals who are insulin resistant may have reduced lean body mass and increased adiposity.  This 
has been termed ‘sarcopenic obesity  172, and its presence is consistent with the strongly elevated plasma 
leptin levels observed in the individuals with high HOMA from both ethnic groups.  Conversely, levels of the 
insulin sensitizing hormone adiponectin fall in both high HOMA groups.  One possibility raised by our findings 
is that sarcopenic obesity could represent a condition of increased protein catabolism associated with insulin 
resistance, a finding that is supported by the aforementioned study showing that net protein balance is 
diminished in individuals with type 2 diabetes mellitus 171.  Also consistent with this idea, insulin resistance is 
independently correlated with poor muscle strength and with accelerated loss of muscle strength and quality 
in older subjects with type 2 diabetes 173-176.  
 
Down-regulation of the growth hormone axis has also been implicated in the link between insulin resistance 
and sarcopenia.  Levels of IGF-1 were reduced in insulin resistant individuals in the present study, similar to 
prior findings in obese, insulin resistant North American subjects 58. This could potentially result in decreased 
anabolic utilization of amino acids, including BCAA, for protein synthesis and cell growth, contributing to their 
rise in the circulation.  However, these differences disappeared after adjustment for age and BMI.  
Interestingly, Chinese subjects had higher IGF-1 levels than Indian subjects, possibly contributing to the 
particular susceptibility of the latter group to develop metabolic diseases such as type 2 diabetes mellitus.  
We also considered other possible explanations for the increased protein catabolism observed in these 
individuals.  It has been suggested that increased inflammation associated with obesity and insulin resistance 
may result in accelerated muscle catabolism 177, 178.  However, the levels of pro-inflammatory cytokines were 
only minimally elevated in our insulin resistant individuals.   
 
When BMI is controlled as in the current study, no correlation beween free fatty acid levels and HOMA 
isevident, at least for the two ethnic groups studied here.  Increases in free fatty acids have been reported in 
obese and insulin resistant subjects in many prior studies, leading to extensive studies on the potential 
“lipotoxic” effects of these agents in development of insulin resistance 179-184.   Another striking finding of our 
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study is the dramatic lowering of IGFBP1 in insulin resistant compared to the more insulin sensitive groups, 
an observation made for both ethnic groups.  Insulin is known to suppress production of IGFBP1 in the liver 
185.   These findings suggest that the elevated plasma insulin in insulin resistant individuals is largely effective 
for suppression of lipolysis and free fatty acid levels, as well as hepatic IGFPB1 production.   However, these 
same elevated insulin levels fail to control the levels of BCAA and related amino acids.   Whether this is 
indicative of early and selective insulin resistance at the level of suppression of protein turnover and amino 
acid catabolism or whether the reduced IGF-1 levels play a more prominent role is a matter that will require 
further investigation.  
 
Several limitations of the study should be noted.  Firstly, we have only studied men, and the relevance of tese 
findings to women is not known at this time.  Secondly, we have only studied these individuals in the fasting 
or post-absorptive state.  We have previously shown that high fat feeding results in abnormalities in lipid 
metabolism that is primarily observed in the fed state 180.   Additional studies in the fed state are likely to yield 
even greater insight into the metabolic perturbations involved in insulin resistance.  Thirdly, HOMA is an 
imprecise method for assessing insulin resistance.  However, we feel that the selection of individuals from 
opposing tertiles of HOMA index allowed us to clearly differentiate insulin sensitive and insulin resistant 
individuals.  The observation that these groups truly differed in terms of insulin resistance are further 
supported by the clear differences in the levels of blood lipids (triglyceride and HDL-C) and adiponectin 
between groups. 
 
In conclusion, extensive evidence supports the role of free fatty acids and inflammation in the pathogenesis of 
obesity associated insulin resistance.  Our study complements this knowledge by showing that insulin 
resistance is not always associated with obesity, and when insulin resistance develops at relatively low body 
weight, IR is no longer associated with excess free fatty acids and inflammation but instead with a metabolic 
signature that suggests enhanced protein catabolism.  This enhanced protein catabolism, and the 
corresponding hyperaminoacidemia, may have several pathophysiologic consequences  55, 56, 58, 186.   Studies 
in animals suggest that elevated BCAAs may increase IR resistance through increased mTOR and JNK 
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activity.    In particular, elevated BCAAs could potentiate the effects of a high fat diet on insulin resistance 58, 
which may be particularly relevant in Asian Indians (who eat a diet higher in saturated fatty acids in our study) 
and may contribute to the development of greater degrees of insulin resistance at relatively low body weight.  
Furthermore, the increased flux of gluconeogenic precursors to the liver may increase the contribution of 
gluconeogenesis to hepatic glucose output.  Finally, this enhanced protein catabolism may contribute to the 
link between insulin resistance and sarcopenia.  While previous studies have focused mainly on dietary 
protein intake in relation to IR 56, our study suggests that strategies that reduce muscle protein catabolism and 
increase muscle protein synthesis might be useful in combating development of insulin resistance even in the 
absence of obesity. Consistent with this idea, the inclusion of resistance training in addition to aerobic training 
optimizes the benefits of exercise on insulin resistance 187.  Further work will be required to fully understand 
the utility of such therapies for influencing metabolic variables associated with insulin resistance described in 
this study.   
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5.1.5  Study 5 
 
We had previously established that SNPs at the APOA1/A4/C3/A4 locus were important determinants of 
plasma triglycerides in our population76. This study extends our previous findings in several ways.  Firstly, 
we have found that SNPs at the APOA5 locus are, by far and away, the most important common variants 
associated with plasma triglycerides within this gene cluster.  In fact, we believe that our data supports 
the hypothesis that SNPs at the APOA5 locus explain most of the association signals previously observed 
with SNPs at other loci within this gene cluster.  This should not come as a total surprise.  Talmud et al121 
previously reported that SNPs at the APOA5 locus probably explained the associations between SNPs at 
the APOA4 locus and plasma TG.  What was rather surprising was that this was the case even for 
polymorphisms at the APOC3 locus. Our study included the SstI polymorphism at the APOC3 locus as 
well as the promoter polymorphisms that have been implicated in the regulation of APOC-III expression 
by insulin and were thought to be functional 78.  Furthermore, Olivier had previously genotyped 49 SNPs 
across the APOA1/C3/A4/A5 cluster and reported relatively high LD across the cluster.  Their analyses also 
supported the presence of recombination events between APOC3 and APOA5 disrupting the cluster, which is in line 
with the relatively low degree of linkage disequilibrium between the SNPs at the APOA5 locus and SNPs at 
the APOC3 locus.  For example, the R2 between rs662799 and rs5128 (SstI) is only 0.13.  Our study thus 
shows that genetic variants with relatively large effects, (rs662799 at the APOA5 locus alone explains 
close to 2% of the variance of TG), can result in association signals at distant loci despite low LD, and 
that the demonstration of relevant biological functionality, as for the APOC3 promoter polymorphisms, 
does not protect this.   
 
It is not clear how these polymorphisms result in altered TG.  While it has been reported that APOA-V 
present  on TG rich lipoproteins may enhance LPL activity, either directly or by facilitating the binding of 
VLDL to LPL attached to heperan sulphate proteoglycans188.   This could result in enhanced lipolysis of 















The 2 polymorphisms at the APOA5 locus (rs2075291 and rs662799) merit some additional comment.  
They both show a strong association with TG and in both instances, these associations remain 
statistically significant even when adjusted for the presence of the other SNP.  This has been taken as 
evidence that these SNPs contribute independently to TG and perhaps represent 2 functional SNPs at 
this locus.  However, closer examination of the data shows that, even though the association between 
rs662799 and TG remains statistically significant after adjustment for rs2075291, there is a significant 
reduction in the association signal with the p-value increasing from 9.6x10-19 to 7.1 x 10-11, suggesting 
that at least some of the association signal for rs662799 is explained by rs2075291.  The R2 between 
these 2 SNPs is 0.14 (in the region of that between rs662799 and rs5128 at the APOC3 locus) and we 
believe that his could represent a situation where a single functional SNP with a large effect could explain 




Our data does not rule out the possibility that more than 1 variant within this cluster shows an association 
with blood lipids.  In fact, for HDL-C, there is a polymorphism in the APOA1 promoter (rs17243123) which 
shows a statistically significant association with HDL-C (borderline for TG) which hardly changes where 
adjusted for the APOA5 SNPs, which is hardly surprisingly given that the R2 between this SNP and the 2 
APOA5 SNPs is only 0.0046.  Thus, it seems that there are at least 2 variants within this cluster that 
affect levels of HDL-C.  One is at the APOA5 and probably has it major effect through elevations of TG 
rich lipoproteins, which in turn provides additional substrate for neutral lipid transfer between HDL and 
VLDL.  The other is at the APOA1 locus which appears to have an effect that is largely independent of 
TG. 
 
Our data also shows that rs662799 modulates the association between central obesity and elevated TG.  
The presence of the rare allele for this SNP is associated with a higher TG in the presence of greater 
waist circumference.  Such a gene-environment interaction may explain why some features of the 
metabolic syndrome are present, even in individuals with relatively low levels of central obesity 193, 194. 
 
In conclusion, our study clearly implicates the APOA5 locus in the pathogenesis of elevated TG and low 
HDL-C.  One or more SNPs at this locus explain most of the associations previously observed between  
SNPs at the APOA1, APOA3 and APOA4 loci and TG, despite the fact that some of these other SNPs 
have demonstrated functional significant, that these gene clusters span a large distance (over 60kb) and 
that the LD is relatively low (R2 in the region of 0.15 or less).  These findings may have significant 
implications for efforts to identify functional polymorphisms that are responsible for the association signals 
found in completed and ongoing genome-wide association studies.  Furthermore, the APOA5 SNPs also 
connote of developing elevated TG and low HDL-C in association with central obesity.  This may explain 
the observation that some individuals develop dyslipidemia at relatively low levels of obesity, and also 
suggest that targeting APOA-V expression might be a useful strategy for the treatment of dyslipidemia 




5.2  Bringing it all together 
 
Through a series of studies, we have demonstrated that the metabolic syndrome is both common, and 
important for defining the risk of CVD in the Singapore population, as it is in other populations.   
57.6% of ischemic heart disease events are attributable to the presence of the metabolic syndrome.  We 
have also shown that central obesity is an important component of the metabolic syndrome but it’s 
presence is not essential.  In the absence of central obesity, individuals can still develop multiple features 
of the metabolic syndrome and they are at just as much risk for CVD as those without central obesity.  
Our studies have identified two pathways that could result in this situation.  Firstly, we have shown that 
insulin resistance, and with it many of the features of the metabolic syndrome, is associated with a 
metabolic signature suggesting increased protein catabolism and a sarcopenic form of obesity.  Secondly, 
we have shown that polymorphisms at the APOA1/C3/A4/A5 loci are associated with the dyslipidemia 
associated with the metabolic syndrome that that, a polymorphism at the APOA5 locus may increase an 
individuals susceptibility to develop dyslipidemia in the face of central obesity.    Finally, we have also 
shown that smoking and alcohol intake are associated with the presence of multiple features of the 
metabolic syndrome in the absence of obesity.  These pathways are illustrated in figure 9.  The schema 
begins with a healthy individual at the top of the figure.  A central portion of the pathway involves energy 
excess which leads to the development of obesity. In turn, this leads to insulin resistance (involving 
excess free fatty acids and inflammation).    In turn, insulin resistance causes the other features of the 
metabolic syndrome.  This portion of the pathway is very much in line with the IDF definition of the 
metabolic syndrome.  However, the AHA/NHLBI recommendation, recognizes that these metabolic 
abnormalities can occur in the absence (or at least at lesser levels) of obesity.  Lifestyle factors (smoking 
and alcohol in study 2), abnormalities of protein metabolism and polymorphisms at the APOA1 and 
APOA5 loci may facilitate this pathophysiologic process either directly or by modulating the impact of 




Figure 9.  Unifying hypothesis for studies in this thesis. 
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Chapter 6  LIMITATIONS AND METHODOLOGICAL CONSIDERATIONS 
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6.1  Bias and confouding 
All observational studies (such as those used in the studies descrided in this thesis) are prone to bias and 
confounding.  In the following sections, I will discuss some of these issues in relation to the studies 
conducted and described. 
 
6.1.1  Selection bias 
Despite efforts to select a random sample of the Singapore population in all the studies used in this 
thesis, response rates were in the region of 60%.  Some efforts were made to determine whether there 
was a non-response bias.   In NHS98, non-participants were contacted to obtain information regarding 
their demographic and socio-economic profile, diabetes and hypertension status.  Characteristics of the 
non-participants were similar to the survey participants.  Nevertheless, we cannot be certain that the 
participants did not differ from thenon-participants in other ways.  The healthy volunteer effect, where 
participants are healthier than the general population, is a well known phenomenon.  Indeed, we know 
that in SP2, participants who provided blood samples and participated in the health examination, were 
less likely to report a history of diabetes mellitus and hypertension.  This may result in a 
misrepresentation of the population’s health/risk-profile and we may have underestimated the prevalence 
of disease in our population.  
 
This type of bias may be less important studies 4 and 5, which are focused more on the etiology of the 
disease.  In general, we feel that it was because the subjects for this study were not ascertained on the 
basis of the disease, that selection bias is unlikely to be a major issue in relation to the validity of the 
findings from these studies.    It is possible that the rather low response rate (particularly in study 4), may 
limit the generalizability of the findings.  After all, SP2 was a study in which less than half the eligible 
participants provided blood samples.  Nevertheless, even if we believe that our findings do not apply to 
those who did not attend the health examination (which we believe is very unlikely given the similarity of 
130 
 
some of our findings to those from studies conducted in other populations), 50% is still a sizeable portion 
of the population and our findings would still be an important health issue. 
 
6.1.2  Misclassification or  measurement error 
The possibility that measurement error or misclassification could result in some degree of bias must also 
be considered.  In relation to the exposures (metabolic syndrome and other CVD risk factors), some 
laboratory error could have occurred.  We believe that such errors are random (since the measurements 
were made without any knowledge of the subjects health status).  Furthermore, the use of standardized 
methodology in all 4 population studies would tend to reduce the measurement error.  This was possible 
because many of the investigators (and sometimes the research staff) were common across the studies.  
Finally, the use of accredited labs with good quality control measures (as evidenced by the small 
coefficients of variations for the various assays carried out) would also tend to reduce such errors.  
Nevertheless, for some variables which show considerable intra-individual variation, such as plasma 
triglyceride, the fact that measurements were made at only a single time point would add to the 
measurement error.  We do believe that these measurement errors are non-differential (unless the 
disease or genetic variant studied also affects the variability of the measurement-there is no real evidence 
for this) and as such, these measurement errors are likely to bias the association towards the null 
hypothesis.  Taken together with the potential for a health volunteer effect described in the preceding 
section, it is possible that we underestimated the population attributable risk associated with the 
metabolic syndrome in studies 1 and 3.  However, this does not change our conclusion that the metabolic 
syndrome is both common, and important for the health of the Singapore population. 
 
In carrying out these studies, we also had to deal with the fact that the ascertainment of IHD events in this 
study was carried out using data from several registries, which could be unreliable.  We are currently 
unable to provide direct evidence as to the reliability of the registry data.  However, we can say that data 
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from the myocardial infarction registry was derived using the WHO MONICA protocol.  The methodology 
is therefore well established. Furthermore, submissions to the central claims processing system and its 
predecessor, the hospital in-patient discharge system are a regulatory requirement for all hospitals in 
Singapore and most, if not all, hospital admissions are represented.  The discharge diagnoses are 
completed by doctors directly involved in the management of the patients admitted to the hospital and we 
believe that they are reasonably accurate.  We concede that patients who are overseas at the time of 
their IHD event would be missed.  However, our own experience as clinicians suggests that these would 
be small in number.  Nevertheless, some degree of misclassification is likely to have occurred.  This could 
bias the results in one of two ways.  If the misclassification is non-differential (as we believe it is) then it 
would tend to bias the associations towards the null hypothesis which, as described in the preceding 
paragraph, would lead to us underestimating the impact of the metabolic syndrome on CVD.  On the 
other hand, it is possible that the diagnosis of CVD is made more readily, or more like to be suspected, in 
patients with features of the metabolic syndrome such as diabetes, hypertension or dyslipidemia.  This 
would tend to inflate the associations observed.  While we cannot exclude this possibility, we have found 
that the effect estimates associated with the metabolic syndrome on CVD are similar to those observed in 
other studies (as discussed in study 1).  In addition, other studies that we have carried out using this 
dataset looking at different risk factors 88, 89 also show that the effect sizes associated with these risk 
factors were similar to those observed in studies with much more detailed assessment of outcomes such 
as the Framingham Heart Study.  Furthermore, we have also shown that the metabolic syndrome is 
associated with mortality (which is much less prone to misclassification than CVD)195.  As such, we 
believe that any bias that has occurred to misclassification of the outcomes is likely to be similar to those 
observed in other studies and unlikely to significantly affect our conclusions. 
 
One other issue that we face, due to the fact that studies 1 and 3 are based on registry linkage, is that 
some of our study subjects may have emigrated.  In this instance, we would not have captured the 
occurrence of IHD events, had they occurred.  We do not feel that this has a large impact on the 
conclusions drawn for several reasons.  Firstly, the emigration rate form Singapore is relatively low (<5%).  
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Secondly, it is our belief that emigration would be non-differential in terms of the presence or absence of 
the metabolic syndrome.  As such, any impact would be to bias the association towards the null 
hypothesis, resulting in an underestimate of the effect of the metabolic syndrome.  Thus, our conclusions 
from these studies remain valid. 
 6.1.3 Confounding 
Confounding may also be responsible for some of the findings observed.  In fact, in genetic association 
studies, we exploit this to delineate the importance of a particular locus to a disease.  For example, if we 
accept the hypothesis suggested in study 5, that a single functional variant is responsible, through linkage 
disequilibrium, for the associations observed between plasma TG and rs2075291 and rs662799 at the 
APOA5 locus, then the observed associations between these 2 SNPs and TG are both a consequence of 
confounding.   
 
Confounding takes on a special meaning in genetic association studies.  Population stratification is a 
particular form of confounding that affects genetic association studies.  This is particularly relevant given 
that Singapore is a multi-ethnic population, and the three ethnic groups exhibit differences in the 
prevalence and levels of various metabolic syndrome related traits.  Thus, any SNPs that have different 
allele frequencies in different ethnic groups would exhibit associations with these traits, which are a 
consequence of confounding by ethnic group.  To a large extent, study 5 is protected against this kind of 
confounding.  Firstly, we restricted the study to Chinese.  This does not exclude the possibility of 
population stratification occurring as a consequence of sub-sets of the Chinese population having 
different population histories.  However, we have recently carried out genome-wide association studies in 
our Singapore population, which shows that the Chinese population in Singapore is quite homogenous 
genetically.  Thirdly, many of the associations observed in study 5 replicate those carried out in other 





It is unlikely that the associations that we have described, between the metabolic syndrome and CVD, are 
a consequence of confounding.  This is because multiple randomized controlled trials targeting the 
features of the metabolic syndrome in patients with type 2 diabetes mellitus (the ultimate patient with the 
metabolic syndrome), such as blood glucose 196, hypertension197, dyslipidemia 198, 199 or the 






6.2  Establishing the temporality of the associations observed 
In addition to dealing with bias and confounding, one of the challenges of observational studies is to 
establish that a risk factor is antecedent to the development of the disease being studied.  Several of 
these studies are cross-sectional studies (study 2, study 4 ).  Even though the associations are robust, 
the temporal relationship between risk factor and disease cannot be established.  As such, it remains 
possible that the associations between the features of the metabolic syndrome and lifestyle factors (study 
1) and metabolic abnormalities (study 4) are a consequence of reverse causation.  Fortunately, these 
observations are not made in isolation.  For example, the impact of hyper-aminoacidemia might have on 
insulin resistance (described in study 5) is supported by experimental models in animals, which not only 
replicate our findings in humans, but provide a mechanistic basis for this association (thus giving 
biological plausibility).  Nevertheless, it will be important to follow up these studies with experimental 
study designs that will formally test the causality of the associations observed.  Although study 5 is also a 
cross-sectional study, in this instance, we are dealing with somatic mutations which have been present 
since birth and as such, establishing temporality is not an issue. 
6.3  Issues related to multiple testing 
Multiple testing can give rise to false positive findings.  This issue has been highlighted by recent genetic 
association studies which have examined the associations of millions of genetic variants in association 
with multiple phenotypic traits.  Two approaches have been taken to reduce the likelihood of false positive 
findings related to multiple testing.  One is to take a more stringent cut off for defining statistical 
significance.  This was carried out in relation to the genetic association studies in study 5, in which we 
used a p-value <0.001 (Bonferoni correction) to declare an association statistically significant, which we 
believe is actually rather conservative (table 19 and 20).  In addition, the associations that we report are 
in well validated loci/variants.  As such, we do not believe that the chance of a false positive finding in this 
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regard is minimal.  However, we do appreciate that the interaction between variants at the APOA5 locus 
and waist circumference (figure 8) is novel and despite a p-value of 0.002 for the test of interaction and 
replication of this observation in an independently collected population with similar measurements is an 
important next step.  The issue of multiple testing has been much less prominent in non-genetic studies, 
in part because the technologies that allow the testing of millions of hypotheses in parallel are less readily 
available.  Nevertheless, multiple testing is an issue in studies such as study 4, in which we have 
measured multiple metabolites and hormones (tables 15 and 16), we have used the traditional p-value of 
<0.05 to define statistical significance.  I recognize that this fails to take into account multiple testing. 
However, several things enhance my belief that these findings are true associations, and not a 
consequence of chance resulting from multiple testing.  Firstly, the major observation that plasma amino 
acids may impact insulin resistance is supported by animal studies, which showed that the 
supplementation of a high fat diet with branch chain amino acids results in greater insulin resistance in a 
rat model of obesity and insulin resistance.  Secondly, in addition to the initial observation that formed the 
basis for the hypothesis tested in study 458 since the publication of this data, 2 additional studies 201, 202 
have also found similar association of amino acids and insulin resistance.  Although these latter studies 
are not indentical, in terms of the analytical methods, to ours, I believe that they lend some support to the 




For all these reasons,  despite the limitations described, we believe that the findings of these studies are 





Through this series of studies, we have demonstrated that the metabolic syndrome, is an important risk 
factors for IHD in the Singapore population (and by extrapolation, to much of Asia),  Studies 2 and 3 add 
further to this by providing some insight as to the appropriateness of the various definitions of the 
metabolic syndrome.  I realize that since the time that these studies were published, there has been 
significant tought/controversy with regards the utility of the metabolic syndrome in the clinical setting.  
Increasingly, I believe that the real utility of the metabolic syndrome lies is an a construct within which we 
can attempt to understand the pathophysiology that gives rise to diabetes mellitus and cardiovascular 
disease.  In addition to providing insight as to appropriate definitions, studies 2 and 3 also suggest the 
possibility that some individuals may be more susceptible to develop risk factors for diabetes and 
cardiovascular disease at lower levels of obesity.  Studies 4 and 5 provide some potential pathways 
through which these may occur (protein metabolism and genetic factors) and I hope that these will form 
the basis of future investigation in this field. 
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